成立时间 01
2017 year [CO001] 尽调报告
United Imaging Intelligence
医学影像 AI 子公司，产品覆盖广但独立经营数据不透明
United Imaging Intelligence 已具备真实的部署规模和可信的平台，但在缺乏独立经营数据的情况下，公开证据仍不足以支撑对外报 $1.4B 估值的投资判断。
覆盖范围与披露说明
基于更新后的公开证据刷新此前报告。最强的公开信号仍是据报道于 June 2025完成的融资及估值，但独立 收入、利润率、客户数量和治理信息仍未披露。
封面要素
公司概况
United Imaging Intelligence 是一家总部位于上海、2017 年成立的医学影像 AI 子公司，其分销、产品集成和研发能力与 United Imaging Group 紧密相连。公开证据支持其于 June 2025 完成 $139 million A 轮融资，据报道估值为 $1.4 billion；但当前独立收入、ARR、员工数、付费客户数、股权结构表和董事会构成仍不可得。
- 总部
- Shanghai, China
- 产品
- 覆盖诊断工作流、临床研究及设备嵌入式智能的医学影像 AI 软件，贯穿 United Imaging 的产品线。
- 客户
- 医院、放射科以及临床/科研工作流
- 商业模式
- B2B 医疗 AI 软件与工作流集成，收入来自 United Imaging 集团生态内的临床赋能、科研工具和设备嵌入式 部署。
- 阶段
- Series A private
- 融资情况
- 据报道，June 2025 A 轮融资 1.39 亿美元，估值 $1.4 billion。
执行摘要
主要优势
- 医学影像产品覆盖面广，多个模态均已覆盖相应监管要求。
- 与 United Imaging 深度整合，为公司带来渠道、数据和工程杠杆。
- 据报道，2025 年 6 月完成的融资及估值提供了外部市场验证。
主要风险
- 独立口径的收入、ARR、利润率和客户经济性仍未披露。
- 对母集团关联方的依赖，使独立性和定价难以单独厘清。
- 客户留存、付费使用深度及治理披露仍不透明。
未决问题
- United Imaging Intelligence 独立口径的收入、ARR、增长及与母公司相关的收入拆分仍完全未披露。
- uAI 软件的毛利率、实际定价水平以及捆绑销售与付费销售的构成均无公开信息。
- 在 4,000 多个部署点中，付费机构数量、使用深度和留存情况均未知。
- 与母公司 UIH 就分销、知识产权、算力和定价达成的关联方条款未披露。
- A 轮融资后的股权结构表、董事会构成和独立员工人数均未公开披露。
目录
01公司概览
1.1 身份与运营模式
United Imaging Intelligence 成立于 2017 年、总部在上海，是 United Imaging Group 旗下医疗 AI 子公司，而非独立硬件厂商。CMB International 称临床赋能约占收入 60%–70%、科研工具约 20%、设备赋能约 10%；UII 的 AI 已覆盖母集团产品线。结合母集团 2024 年 CNY 2.26 billion 研发投入，公司能获得资本、数据、分销和工程支持，但独立经济性与公平交易商业 traction 难以拆分。[CO001, CO002, CO003, CO005, CO008]
| 指标 | 数值或状态 | 截至 | 置信度 | 缺口或限定 |
|---|---|---|---|---|
| 成立时间 | 2017 | 当前画像 | 中 | 两份独立画像一致报道 |
| 总部 | 上海，中国 | 当前画像 | 中 | 未分配当前主要企业登记资料 |
| 公司状态 | United Imaging Group 的私有 AI 子公司 | 2026 年证据集 | 高 | 独立控制权未披露 |
| 最新披露融资 | $139 million A 轮 | June 2025 | 中 | 交易数据库数据；主要融资文件不可得 |
| 据报道的估值 | $1.4 billion | June 2025 | 中 | 交易数据库报道为投后口径 |
| 独立财务快照 | 收入 RMB 166 million；净亏损 RMB 82.9218 million | 2024 年前九个月 | 中 | 较早的交易报告；未经审计，且不代表当前运行率 |
| ARR、当前收入、员工数、经核实的付费客户 | 2026-10-18 | 低 | 指定公开证据不足以支持 |
数值保留来源期间和单位；null 表示指定证据不足以支持当前独立指标。
[CO001, CO002, CO003, CO010, CO011, CO013]1.2 领导层、资本与治理
公开领导层证据很少：2020 年公告称 Terrence Chen 任 UII America CEO，当前交易画像称 Shen Dinggang 教授负责部分数据算法和临床应用工作。资料没有完整管理团队、董事会、投票结构或继任方案。Multiples 报道 June 2025 E Fund 和 Shangguo Investment Management 领投 $139 million A 轮，估值 $1.4 billion；另一份 2024 年 12 月报告称 United Imaging Healthcare 将投资 RMB 28.4872 million 取得 0.2849%，投前估值为 RMB 9 billion。不同日期和交易口径在缺少底层股权结构表时不应视为估值矛盾。[CO004, CO009, CO010, CO011, CO012]
| 人物 | 公开报道职务 | 相关背景或覆盖范围 | 关键人物依赖 | 证据限制 |
|---|---|---|---|---|
| Terrence Chen | United Imaging Intelligence America 首席执行官 | 领导 2020 年 MGH 波士顿与上海团队合作 | 代表美国科研与市场接口 | 该职务来自 2020 年公告，可能已非现任 |
| Shen Dinggang 教授 | 负责该子公司的部分工作 | 从事数据驱动算法与临床应用的医学 AI 学者 | 技术领导力似乎重要 | 确切职务、当前职责范围和治理权限未披露 |
这是指定资料中提及领导者的部分枚举，不是完整或当前的管理层及董事会名单。
[CO004, CO009]| 利益相关方 | 角色 | 控制权或经济重要性 | 尽调要求 |
|---|---|---|---|
| United Imaging Group / United Imaging Healthcare | 母集团生态与战略投资者 | 提供设备集成、研发规模、分销和数据访问 | 取得关联方协议、转移定价、知识产权所有权和投票权信息 |
| E Fund | 2025 年 6 月 A 轮领投方 | 主要融资参与方 | 确认证券条款、持股、清算优先权和董事会权利 |
| Shangguo Investment Management | 2025 年 6 月 A 轮领投方 | 主要融资参与方 | 确认证券条款、持股、清算优先权和董事会权利 |
| Massachusetts General Hospital | 科研合作方 | 2020 年宣布的外部临床科研关系 | 核实当前状态、后续部署以及后续知识产权归属 |
| 医院与影像科室 | 终端用户与买方 | 商业采用决定软件质量及其脱离母集团捆绑的独立性 | 提供付费站点数、定价、留存、使用深度和母集团渠道归因 |
这是指定证据中点名或暗示的经济重要参与方样本；完整的 A 轮后股权结构表不可得。
[CO003, CO008, CO009, CO010, CO012, CO016]1.3 规模、里程碑与尽调解读
产品广度的证据强于商业质量。CMB 称截至 2024 年底有超过 100 个医疗 AI 产品，覆盖 NMPA、CE 和 FDA；RSNA 2025 和 WHX 2026 的发布展示多模态智能体及 60 多应用的临床门户，但不等于采用、定价或各地获批。2024 年前九个月收入为 RMB 166 million、净亏损为 RMB 82.9218 million；2023 年收入为 RMB 254 million、净亏损为 RMB 136 million。当前收入、ARR、利润率、现金、员工数、付费机构、留存和客户集中度仍是重大缺口。[CO006, CO007, CO013, CO014, CO015, CO016]
八个带日期的里程碑追踪成立、研究合作、融资、产品规模，以及向医疗 AI 智能体的转向。
日期和期间按各来源可提供的精度展示；未对缺失的日或月进行推定。
公司成立 [CO001]
MGH 研究合作公布 [CO009]
独立亏损仍然显著 [CO013]
披露母公司增资 [CO012]
uAI Insight 在 RSNA 展示 [CO015]
WHX 展示更广泛的 AI 产品组合 [CO016]
1.4 展品
02市场分析
2.1 市场边界与现状替代方案
资料将市场边界定义为附着于诊断和治疗工作流的医学影像 AI，而非泛医院软件。纳入支出包括扫描仪内嵌 AI、AI 辅助阅片和报告、科研工具及影像质控层；除非明确回连影像工作流，否则排除 HIS/ERP、支付方分析、消费者健康和非影像行政系统。主要现状替代方案是人工放射科工作流、模态原生软件及无 AI 层的传统设备升级。[CM001, CM002, CM003, CM011, CM016]
| 细分市场 / 类别 | 纳入支出 | 排除支出 | 买方 / 支付方 | 相关性 |
|---|---|---|---|---|
| 设备嵌入式影像 AI | 嵌入扫描仪软件、重建、定位和工作流加速的 AI | 硬件机身收入和非 AI 服务合同 | OEM 关联采购、医院影像负责人、资本设备预算 | 符合 UII 的设备赋能和模态集成切入口 |
| 放射科工作流应用 | 覆盖各影像模态的筛查、诊断、报告和随访工作流软件 | 通用 EHR、HIS、ERP 或计费系统 | 放射科、影像业务线、医院 IT | UII 官方材料将其定位为核心临床工作流层 |
| 科研赋能 | 科研门户、标注、模型开发工作流和影像科研工具 | 湿实验室软件、CRO 服务或无关的生命科学 IT | 学术医院、首席研究员、研究机构、基金资助项目 | 卖方业务组合数据显示科研是独立业务分部 |
| 质量控制与医院运营 | 影像质量控制、网络监督和影像设备运营洞察 | 不涉及影像质量或扫描仪利用率的通用运营软件 | 区域医院网络、集中式影像质控团队、医院运营 | 将市场从单一阅片者诊断用例扩展出去 |
这是结合官方和第三方描述的受证据约束范围表；纳入和排除支出是根据引用的产品与工作流描述得出的分析边界，而非已披露的价目表分部。
[CM001, CM004, CM005, CM009, CM011, CM013, CM016]2.2 买方、用户、支付方与采用路径
买方包括放射科主任、影像业务线负责人、模态管理员，以及区域网络管理者和集中式影像质控团队；科研买方包括学术和临床研究用户。由于 UII 把 AI 嵌入 United Imaging Healthcare 各模态核心软件，支付方审批往往嵌在资本设备、IT 和采购流程中，而非独立 AI 预算。[CM004, CM005, CM009, CM010, CM011, CM013, CM015]
| 细分市场 | 买方 | 用户 | 付款方 | 工作流 | 预算负责人 | 采用触发因素 |
|---|---|---|---|---|---|---|
| 放射科 | 放射科主任或影像业务线负责人 | 放射科医生和技师 | 医院运营预算或科室影像预算 | AI 辅助诊断、报告和随访 | 放射科管理层，IT 和采购参与决策 | 提升吞吐量、报告速度和诊断一致性的需求 |
| 区域影像网络 | 主院或三级医院网络负责人 | 卫星医院及一、二级医院 | 区域医疗系统或网络预算 | 跨院点质量控制、影像监督和升级处理 | 集中式影像质量或网络管理 | 统一分散机构影像质量的需求 |
| 临床和学术研究用户 | 首席研究员或研究项目负责人 | 研究人员、临床科学家和影像实验室 | 科研经费、研究机构或医院研究预算 | 标注、模型开发和研究工作流加速 | 科研管理部门和项目管理层 | 缩短 AI 开发周期并高效利用临床影像数据的需求 |
| 存量设备渠道 | 模态采购方及 OEM 关联利益相关者 | 技师、模态团队和下游临床医生 | 资本设备及配套软件预算 | 将 AI 嵌入各模态核心软件 | 医院采购方和模态资本开支负责人 | 设备更新以及对 AI 影像升级的需求 |
买方、付款方和触发因素字段均根据引用的部署描述推断；本证据池没有 披露正式的 UII 定价目录或具名预算负责人细分。
[CM004, CM005, CM009, CM010, CM011, CM013, CM015]2.3 受证据约束的市场规模视角
公开证据不足以支持独立口径的清晰美元 TAM、SAM 或 SOM。手册称有超过 40 项 AI 技术和 50 多个 AI 辅助应用；分析师报告称截至 2024 年底有超过 100 个医疗 AI 产品，包括 12 项 NMPA III 类、21 项 NMPA II 类、13 项 CE 和 15 项 FDA 认证。低置信度第三方画像称覆盖全球 3,000 多家医院的 100 多个 AI 应用，但该数字由 AI 生成且未获其他资料印证；付费机构数、软件变现附着率和独立收入仍无法拆出。[CM002, CM003, CM004, CM006, CM014, CM016]
| 发布方 | 年份 / 期间 | 地理范围 | 数值 / 视角 | CAGR / 增长信号 | 方法论 | 置信度 | 局限 |
|---|---|---|---|---|---|---|---|
| United Imaging Intelligence 手册 | 2024 年手册快照 | 全球 | 覆盖所有模态医疗设备和放疗设备的 40 多项 AI 技术 | n/a | 官方产品组合对工作流广度的代理指标 | 中 | 能力数量，不是支出或收入数字 |
| United Imaging Intelligence 宣传册 | 2024 年宣传册快照 | 全球 | 融入临床工作流的 50 多个 AI 辅助应用 | n/a | 官方工作流应用数量 | 中 | 未披露付费部署、定价或搭载率 |
| 新浪财经转载的卖方研报 | 2024 年末 | 全球 | 100 多款医疗 AI 产品；12 项 NMPA III 类；21 项 NMPA II 类；13 项 CE；15 项 FDA | 政策驱动的设备更新和不断提高的 AI 采用率被列为顺风因素 | 中 | 以产品和监管数量为基础的分析师市场数据视角 | 不是收入或市场规模披露；部分说法属于分析师解读 |
| IntuitionLabs AI 生成的简介 | 未注明日期 | 全球 | 全球 3,000 多家医院使用的 100 多个 AI 应用 | n/a | 第三方部署覆盖面的代理指标 | 低 | AI 生成的简介，提示内容可能有误，且本证据池没有其他来源佐证 |
本证据池没有来源披露 UII 独立的美元计价 TAM、SAM 或 SOM，因此本表使用产品组合 广度、认证和部署代理指标，而非未经支持的收入推导市场规模。
[CM002, CM003, CM006, CM008, CM014, CM016]由于公开来源未披露 UII 独立的软件美元 TAM，该图按最广覆盖到最窄的受监管或接近变现证据，分层展示可获得的最强商业化和部署代理指标。
各层宽度仅表示层级，不代表数值比例。
这不是按美元计算的 TAM 图。由于来源池未披露独立软件收入、定价或付费机构数量，图中有意混合部署、产品组合、认证和收入结构数量。
[CM002, CM003, CM004, CM006, CM014]2.4 增长驱动、约束与估值相关性
需求时点同时受影像资本开支周期和医院工作流压力影响。2025 年年报称中国设备更新政策释放高端影像、放疗和基层诊疗需求；RSNA 2025 推进报告和医院管理智能体，WHX 2026 增加科研、质控和设备运营门户。但在定价、付费站点数或软件收入分部披露前，估值仍基于采用潜力，而非已证明的市场占有。[CM007, CM008, CM012, CM013, CM016]
2.5 展品
03竞争格局
3.1 竞争格局分散于专业厂商、替代方案与现状之间
指定资料没有一家能在所有维度上与 UII 清晰对标的主导软件竞争者。Dealroom 的接近公司包括 Pixyl、Quibim、Nucs AI 和 Radiobotics；IntuitionLabs 列出 MaxQ AI、JLK、Neurocareai 和 Heuron。买方可拼装专注型影像 AI 工具，人工放射科工作流和医院内部开发也仍是替代方案。[CP001, CP006, CP007, CP011, CP014]
| 替代类别 | 指定来源中的例子 | 规模 / 融资信号 | 目标细分市场 | 差异化信号 | 局限 / 证据提示 |
|---|---|---|---|---|---|
| UII 集成平台 | UII | Dealroom 显示估值区间为 $1-2.5B，已披露融资额为 $100-500M；各目录对公开员工数的估计 相互矛盾 | 采购更广泛工作流软件的医院和影像科室 | 覆盖诊断、研究、报告及母公司设备集成的全栈范围 | 独立经济性和合同条款仍未披露 |
| 纯软件影像 AI 同业 | Pixyl、Quibim、Nucs AI、Radiobotics（Dealroom） | 创业公司式同业集合；指定证据池没有可直接比较的共同融资或收入细节 | 寻求聚焦型影像 AI 工具的放射科团队 | 比 UII 的全工作流叙事更聚焦的软件定位 | 指定证据池中的同业信息深度有限，且并非正面竞争比较 |
| 分诊 / 诊断 AI 同业 | MaxQ AI、JLK、Neurocareai、Heuron（IntuitionLabs） | 竞争者名称仅见于 AI 生成的目录简介 | 比较针对性诊断算法的买方 | 可能更窄的疾病或任务层面竞争 | 指定证据没有提供这些竞争者的产品、定价或客户深度 |
| 现状和内部自建 | 人工报告、本地医院 AI 项目、特定工作流工具 | 依靠现有医疗服务人员和医院 IT 预算，而非供应商融资 | 医疗服务机构将更多工作留在临床和研究团队内部 | 无需批准新供应商；无需购买平台即可承接狭窄用例 | 替代类别根据 UII 正在自动化的工作流步骤推断，而非根据具名供应商披露 |
由于指定证据池呈现的是零散竞争者集合而 非完整供应商普查，表中混合具名同业和替代类别。未知项保留原样，不作猜测。
[CP001, CP006, CP007, CP012, CP014]在指定证据范围内，UII 位于广平台 / 高渠道一角，因为其披露的工作流范围和母公司关联度超过公开目录中点名的专业型同业集合。
- X: 工作流广度
- low: 单一任务
- high: 全流程 / 平台
- description: Evidence-backed ordinal scoring from assigned sources
- scale: ordinal
- Y: 分销杠杆
- low: 独立销售
- high: 装机基础 / 渠道杠杆
- description: Evidence-backed ordinal scoring from assigned sources
- scale: ordinal
| 条目 | 工作流广度 (1–5) | 分销杠杆 (1–5) | 说明 |
|---|---|---|---|
| 1. UII 一体化平台 | 5 | 5 | 覆盖全栈、全谱系，并叠加母公司的渠道杠杆。 |
| 2. 专业影像 AI 同行 | 2 | 2 | 独立目录列出的是专注型软件同行，而不是覆盖同样广泛的平台标杆。 |
| 3. 分诊 / 诊断竞争者 | 2 | 2 | IntuitionLabs 列出针对性诊断竞争者，但指定来源池没有广泛渠道证据。 |
| 4. 医院内部自建 | 3 | 1 | 研究和工作流工具表明，部分医疗机构可以在本地搭建更窄的替代方案。 |
| 5. 现状人工工作流 | 1 | 4 | 即使自动化有限，现有报告和临床流程仍然嵌在日常运营中。 |
| 6. 母公司设备组合 | 4 | 5 | United Imaging 的硬件捆绑是最能强化 UII 地位的渠道。 |
点位坐标是根据指定来源描述作出的序数判断，并非经过审计的市场份额、定价或赢单率数据。
[CP006, CP007, CP009, CP010, CP013, CP014]3.2 UII 以工作流广度和母集团分销实现差异化
UII 的差异化主要是覆盖广度：CT、MR、PET、X-ray、诊断、治疗规划、科研和医院运营均有涉及。产品包括肋骨骨折检测、肺栓塞分诊、CCTA、CT-FFR、钙化评分、PET 摄取分析和神经分诊；RSNA 2024/2025 进一步强调基础模型、结构化报告智能体、医院管理智能体和工作流助手。据母集团关联分析师报告，AI 已全面采用到 United Imaging 产品线；2026 年第一财经报道也称其增强硬件集团高端市场竞争力。[CP002, CP003, CP004, CP005, CP008, CP009, CP010]
| 购买标准 | UII | 专业影像 AI 同业 | 现状 / 内部自建 | 含义 |
|---|---|---|---|---|
| 工作流广度 | 来源支持的覆盖范围包括 CT、MR、PET、X 光、诊断、治疗规划、研究和医院 运营 | 指定来源列出同业名称，但没有显示同等广度 | 通常局限于现有本地工作流范围 | UII 的广度是公开披露中最清晰的差异化点 |
| 疾病 / 模态深度 | Health AI Register 列出多个特定模态应用，包括肋骨骨折、PE 分诊、CCTA、 CT-FFR、PET 和神经分诊 | 部分同业可能深耕单点解决方案，但指定证据池没有一致记录 | 深度取决于本地临床医生和数据科学资源 | UII 看起来更广，但同业专长仍可能赢下狭窄工作流 |
| 监管 / 认证披露 | RSNA 2024 提到 15 个 FDA 获批和 13 个 CE 标记应用；母公司关联分析师研报还补充了 NMPA 数量 | 指定证据池没有可比同业披露 | 不适用于供应商基准比较 | 就披露的获批广度而言，公开证据更支持 UII |
| 工作流智能体路线图 | RSNA 2024/2025 材料描述了基础模型、报告智能体、医院管理智能体和 工作流助手 | 指定同业列表中没有出现同等路线图细节 | 没有统一智能体层，人工或定制工具也能覆盖部分工作流 | UII 正试图把竞争从单点工具推向平台控制 |
| 分销杠杆 | 母公司存量设备基础和设备捆绑证据明确 | 指定同业来源没有记录同等渠道优势 | 医院掌控内部优先级，但规模局限于本地 | UII 最强的护城河主张是渠道杠杆，而非透明的商业证明 |
由于指定证据池缺乏清晰的正面对比披露，同业信息不足的单元格保留为未知。 本比较有证据支持，但并不完整。
[CP002, CP003, CP004, CP005, CP008, CP009, CP013, CP014]| 商业角度 | UII 公开证据 | 同业 / 替代方案公开证据 | 含义 |
|---|---|---|---|
| 独立价目定价 | 指定来源没有发布 UII 价目表或逐模块费率 | 指定证据池没有出现可比同业价目表 | 本章无法直接比较定价能力 |
| 打包方式 | 证据指向平台模块、工作流门户和母公司硬件集成，而非简单的 自助式 SKU | 同业证据仅限于名称或更窄的应用示例 | 捆绑方式和解决方案范围可能比标价更重要 |
| 市场进入证明 | 官方发布重点介绍 RSNA 发布、学术合作和母公司市场整合 | 指定证据池没有提供所列同业可比的 GTM 细节 | UII 可能依靠企业客户背书和渠道杠杆销售 |
| 转换成本证明 | 指定来源没有公开披露留存、续约、搭载率或模块渗透率等指标 | 同业方面也没有披露转换成本指标 | 尽管产品广度看似合理，护城河持久性仍缺乏证据 |
本表保留证据缺口，而不是制造定价比较。商业结论应 视为打包方式线索，而非经验证的合同经济性。
[CP005, CP011, CP012, CP013]3.3 护城河持久性尚有可能，但未获独立基准验证
护城河逻辑合理但不完整。UII 具备产品广度、监管许可、学术合作，并能把 AI 捆绑进 United Imaging 硬件和医院工作流；但资料无法验证其是否带来更高独立软件定价、更高胜率、更低流失率或更好临床结果。因此，现有证据支持渠道和范围优势，却还不足以断言 UII 已锁定持久的竞争优势。[CP004, CP005, CP010, CP012, CP013]
04财务
4.1 收入架构可见，但收入质量不可见
公开证据显示三条商业路径：临床赋能约 60%–70%、科研赋能约 20%、设备赋能约 10%。母集团影像产品、云和影像中心提供数据及部署渠道，UII 也共享集团软件、硬件和其他资源；但没有资料区分第三方软件销售、设备捆绑、母集团项目、实施服务或其他关联方活动。[CI002, CI006, CI008, CI012, CI014, CI015]
| 收入流 | 机制 | 单位 | 当前数值或状态 | 证据质量 | 尽调要求 |
|---|---|---|---|---|---|
| 临床赋能 | AI 辅助诊断和放射科工作流应用 | 合同、模块或部署；具体单位未披露 | 一份分析师研报称，2024 年末按收入计约占业务的 60-70% | 单一来源的方向性结构；留存证据未经审计 | 将分部收入与发票、付费机构、续约和已确认收入核对 |
| 研究赋能 | 支持医生研究的工具和服务 | 项目、许可或服务；具体单位未披露 | 一份分析师研报称约占业务的 20% | 单一来源的方向性结构；缺少定价和利润率 | 提供合同、交付成本、经常性收入占比和毛利率 |
| 设备赋能 | 嵌入 United Imaging 设备或用于升级该设备的 AI | 搭载、捆绑、许可或转让；具体单位未披露 | 一份分析师研报称约占业务的 10% | 分析师结构数据，加上公司关于母公司渠道整合的证据 | 拆分第三方软件收入、硬件增值收入和关联方转移收入 |
| 母公司赋能部署 | 母公司影像产品、云和影像中心提供数据及落地场景 | 经济单位未披露 | 战略路径有描述，但未说明收入贡献 | 官方定性证据，不是收入披露 | 量化渠道费用、搭载率、数据或算力费用及第三方收入分成 |
细分市场占比是分析师近似估计；留存来源没有提供经审计的独立收入、 实际定价或完整收入确认政策。
[CI002, CI006, CI008, CI014, CI015]公开证据支持一条由母公司赋能、从资本和共享资产通向三条商业路径的链路，但这条链路在经审计的独立收入和毛利之前就中断了。
| 节点 / 连接 | 节点 / 起点 | 终点 | 说明 |
|---|---|---|---|
| 节点 1 | 母公司及关联方资本 [capital-support] | $45M founding investment; later RMB70M planned UIH participation 融资事件显示公司可以获得协同资本，但不代表当前流动性。 | |
| 节点 2 | 集团数据和部署资产 [shared-assets] | Imaging products, cloud, imaging centers, software, and hardware resources 官方及第三方来源将其描述为 UII 的投入和渠道。 | |
| 节点 3 | 医疗 AI 产品组合 [ai-portfolio] | More than 100 products or applications reported 不同来源的统计口径各异，不能据此确认付费使用。 | |
| 节点 4 | 三条已披露商业路径 [commercial-lanes] | Clinical 60-70%; research about 20%; equipment about 10% 来自一份分析师笔记的 2024 年末近似构成。 | |
| 节点 5 | 医院和设备部署 [customer-activity] | Deployment breadth reported; paid usage and retention unavailable 公司及低等级画像证据提供了业务活动代理指标，而非经审计收入。 | |
| 节点 6 | 独立财务产出 [financial-output] | Revenue, gross margin, cash burn, and runway undisclosed 需要私有记录才能补完整条链路。 | |
| 连接 1 | 母公司及关联方资本 [capital-support] | 集团数据和部署资产 [shared-assets] | 提供资金并支持 |
| 连接 2 | 集团数据和部署资产 [shared-assets] | 医疗 AI 产品组合 [ai-portfolio] | 提供数据、基础设施和渠道 |
| 连接 3 | 医疗 AI 产品组合 [ai-portfolio] | 三条已披露商业路径 [commercial-lanes] | 组织成 |
| 连接 4 | 三条已披露商业路径 [commercial-lanes] | 医院和设备部署 [customer-activity] | 通过……部署 |
| 连接 5 | 医院和设备部署 [customer-activity] | 独立财务产出 [financial-output] | 公开证据无法量化转化为 |
分部占比为近似值且来自单一来源；部署指标不视为付费客户数、收入或利润率数据。
[CI001, CI002, CI003, CI006, CI007, CI009, CI010, CI012, CI014]4.2 定价与市场进入经济性仍属非公开信息
市场进入优势可能来自 United Imaging 设备和医院关系，而非独立销售体系。资料支持设备附着和企业部署路径，却没有合同量、价格、折扣、销售周期、渠道费或续约条款，因此无法确定是经常性软件收入、项目收入、捆绑硬件溢价、内部转移收入还是组合，也无法量化 CAC 或回本周期。[CI002, CI008, CI012, CI014, CI015]
| 产品或路径 | 价格或单位 | 合同模式 | 标价与实际实现价 | 折扣或未知 | 含义和尽调要求 |
|---|---|---|---|---|---|
| 临床 AI 应用 | 医院、科室、模块或使用量计费基础未披露 | 标价和实际实现价均未披露 | 折扣、实施费用和续约条款未知 | 获取价目表、样本合同、客户群组及按模块确认的收入 | |
| 研究赋能 | 许可、项目、服务或赞助研究计费基础未披露 | 留存来源中未找到公开定价 | 交付范围、人员配置和知识产权条款未知 | 将经常性许可与利润率较低的项目或服务工作拆分 | |
| 嵌入设备的 AI | 捆绑、搭载、转移定价或升级计费基础未披露 | 未披露独立 AI 价格或硬件增值 | 母公司渠道费用和关联方转移条款未知 | 核对设备搭载率、软件分摊和公司间经济性 |
空值表示留存证据没有说明价格；不代表产品免费，也不代表没有 对价发生转移。
[CI002, CI008, CI014, CI015]4.3 资本支持已披露，但充足性与单位经济性未知
资本记录说明 UII 能获得关联方支持，却不能证明财务自立。United Imaging 表示，其曾投入 $45 million 设立这家 AI 子公司。第一财经随后报道，United Imaging Healthcare 计划投资 RMB70 million，交易后持股 0.70%，累计持股将达 0.9849%；报道还将 United Imaging Group 和 Shanghai Lianhe 列为参与方。这些交易说明 UII 可调动战略协同资本，但留存的八份资料均未披露当前现金、账面亏损、经营现金消耗、债务、担保、现金跑道或下一轮融资触发条件，也没有独立收入、ARR、毛利率、服务交付成本、营运资金、资本开支和获客经济性。因此，已募集资金不能视为当前可用现金。[CI001, CI003, CI004, CI005, CI013, CI014]
| 指标 | 公开数值 | 置信度 | 重要性 | 尽调要求 |
|---|---|---|---|---|
| 独立收入或 ARR | 低 | 没有公开营收基数可用于增长、质量或估值分析 | 要求提供按收入流、地域、客户类型和关联方占比拆分的经审计季度收入 | |
| 毛利率和服务交付成本 | 低 | 软件、实施、算力、支持和设备捆绑的经济性可能存在重大差异 | 要求提供按收入流拆分的毛利率桥接表，包括算力、实施、支持和渠道成本 | |
| CAC、销售周期和回本期 | 低 | 母公司分销可能降低获客成本，但公开证据没有量化这一收益。 | 要求提供按渠道拆分的漏斗转化率、销售费用、周期长度、搭载率和回本期 | |
| 现金、烧钱速度、现金续航期、债务和下一轮触发条件 | 低 | 历史融资渠道无法说明当前流动性或融资依赖 | 要求提供当前资产负债表、月度现金消耗、债务和担保、已批准预算及融资计划 |
空值表示八个留存章节来源中没有相关信息；创始投资和后续资本参与 属于融资事件，不是当前现金或现金续航期 的衡量。
[CI001, CI003, CI004, CI005, CI013, CI014]4.4 财务结论与投资评估障碍
财务逻辑在战略上合理，但公开证据不足以量化评估。产品广度、医院部署、患者体验参考和母集团渠道集成不能替代付费客户、使用率、留存或收入披露。Reuters 及 Yahoo 联合转载称管理层因技术尚不成熟而抵制激进 AI 推广；重复转载是一份报道，不是独立佐证。尽调应把分部组合与经审计独立收入对账，拆分关联方经济性，核验各业务流毛利率，并测试现金和融资能力是否覆盖经营路径。[CI007, CI009, CI010, CI011, CI013, CI014, CI015]
4.5 展品
05产品与技术
5.1 工作流覆盖广且面向临床
UII 产品覆盖筛查、分诊、图像分析、治疗规划、科研和医院运营。uAI EasyTriage-Rib、uAI Easy Triage ICH 为放射科医生优先标记危急发现，uAI Portal 支持 CT 血管造影阅片和术前分析；第三方称有超过 100 个 AI 应用及 60 多应用的 uAI Clinical Portal，商业定位是覆盖多种影像模态的科室或医院级软件层。[CE001, CE002, CE003, CE004, CE005, CE006]
| 模块 / 资产 | 主要用户 | 状态 / 成熟度 | 差异化 | 尽调缺口 |
|---|---|---|---|---|
| 危重发现分诊工具（uAI Easy Triage ICH；uAI EasyTriage-Rib） | 放射科医生 / 急诊影像团队 | 具名 FDA 关联产品；独立目录显示分别于 2021 年和 2024 年发布 | 标记疑似 ICH 或肋骨骨折病例，以重新排序工作列表和通知 | 需要站点层面的敏感度 / 特异度、假阳性负担和续约证据 |
| uAI Portal | 放射科医生 / 血管和术前影像用户 | 具名 FDA 关联产品；独立目录显示于 2024 年发布 | 在一个工作流界面中结合 CT 血管造影阅片、3D 可视化和 AI 血管分割 | 需要 PACS/RIS 互操作细节，以及各专科常规生产使用的证明 |
| uAI Clinical Portal 及更广泛的应用库 | 放射科 / 医院买方 | 宣称为商业平台；指定证据池没有逐个列出应用成熟度 | 覆盖各模态和疾病领域的产品组合广度；门户上有 60 多个应用，整体超过 100 个 | 需要逐产品获批矩阵、付费结构和弃用历史 |
| 基础模型和智能体层（uAI Insight、uAI Avatar、医院管理智能体） | 放射科医生 / 医院运营 / 临床研究团队 | RSNA 2025 展示了演示阶段路线图 | 从单任务 AI 走向多模态推理、报告生成和运营分析 | 需要 GA 时间、临床医生参与环路的控制措施及各国可用性 |
本表将独立目录中的具名产品，与第三方简介和公司活动材料中的更广泛产品组合主张结合； 指定证据池没有公开产品目录，因此各模块的成熟度 记录不均衡。
[CE002, CE003, CE004, CE005, CE006, CE007, CE008]| 用户任务 | 当前工作流 | 公司方案 | 可衡量收益 | 局限 |
|---|---|---|---|---|
| 优先处理急诊头部 CT 检查 | 采集影像后由放射科医生人工查看队列 | uAI Easy Triage ICH 在无增强头部 CT 上标记疑似颅内出血 | 在医院场景中更快通知并提升工作流效率 | 公开证据没有披露站点层面运营指标或按人群校准结果 |
| 优先处理创伤胸部 CT 检查 | 人工查看可能存在肋骨骨折的创伤扫描 | uAI EasyTriage-Rib 标记疑似多发急性肋骨骨折，以进行工作流分诊 | 更早优先处理带有疑似危重发现的创伤检查 | 工具辅助分诊而非诊断；公开准确性披露有限 |
| 解读并规划血管 CT 血管造影 | 人工阅片、测量血管并进行手术规划 | uAI Portal 提供 CT 血管造影查看、操作、评估和 AI 血管分割 | 帮助多个血管床的临床决策和术前分析 | 没有公开工作流交接、集成深度或各站点专科采用情况的实施细节 |
| 开发并落地新的影像 AI 工作流 | 研究工具与人工模型转化落地彼此分离 | UII 将研究工具、多模态模型及 MGH 项目等合作计划结合起来 | 由于数据、算法和已安装系统都在同一集团内，研究到临床的闭环被描述为更快； | 指定证据池中的公开基准和外部可复现性证据仍然有限 |
收益表述保持留存来源中的粒度；指定证据池没有提供经审计的 任何工作流的吞吐量、ROI 或留存分母。
[CE004, CE005, CE010, CE011, CE012]5.2 架构优势来自与母集团系统的集成
最强差异化是部署在 United Imaging Healthcare 的硬件、云和影像中心基础上，而非独特模型架构。集团共享硬件和软件研发平台可缩短嵌入式功能、数据采集和工作流工具的集成周期；代价是产品准备度、数据访问和全球分销都与母集团平台紧密耦合。[CE007, CE011, CE012]
| 层 / 流程 / 组件 | 作用 | 依赖 | 风险 |
|---|---|---|---|
| 母公司硬件和影像中心基础设施 | 为嵌入式 AI 提供存量模态覆盖和数据采集路径 | 资料称 UII 与 United Imaging Healthcare 硬件、云平台和影像中心集成 | 对关联方的依赖可能增加独立评估和替代分析的难度 |
| 共享硬件 / 软件研发平台 | 支持跨模态产品集成和迭代 | 母公司年报称，各产品线复用共同底层架构和共享设计 | 跨产品耦合可以加快发布，但也会集中技术和组织依赖 |
| 临床应用层 | 向终端用户交付分诊工具、门户软件和更广泛的应用库 | 只有部分产品组合的具名产品成熟度可见 | 产品组合广度超过指定证据池中应用层面的公开获批和实施证据 |
| 基础模型与智能体层 | 在现有工作流之上增加多模态推理、报告生成和医院运营编排 | 依靠临床协作、多模态模型和母集团分发，才能从展示走向生产环境 | 路线图的可见度高于商业化准备度；并非所有功能都已记录为获批或可在全球提供 |
| 信任、隐私与合规控制 | 提供基础级信息安全与隐私流程覆盖 | 公开可见的控制措施主要由母集团披露 | 指定来源池未呈现 UII 特有的状态、事件、模型治理和采购安全文档 |
该架构视图综合了关于硬件集成、共享研发平台和已点名 AI 产品的明确来源表述；指定来源池未披露 UII 更深层的独立软件架构。
[CE007, CE008, CE011, CE012, CE013]UII 的公开产品叙事是在母公司的影像装机和合规底座之上，逐层叠加应用软件与智能体软件。
- 影像装机底座
- 母公司硬件、云平台、影像中心和已部署系统共同构成部署与数据基础。
- 模块
- UIH 影像设备及放疗设备
- 用于采集数据的云平台和影像中心
- 全球装机基础和医院覆盖
- 输出
- 嵌入式部署路径
- 特定设备的数据流
- 临床应用层
- 已命名的工作流工具覆盖分诊、CT 血管造影分析及更广泛的应用库。
- 模块
- uAI Easy Triage ICH 工具
- uAI EasyTriage-Rib
- uAI Portal
- uAI Clinical Portal / 超过 100 个应用的应用库
- 输出
- 工作列表优先级排序
- 分割与结构化分析
- 研究与质量层
- Portal 产品将软件能力延伸至研究工作流、影像质量审查和设备分析。
- 模块
- uAI Research Portal 研究门户
- uAI Quality Control Portal 质控门户
- uMetaGenesis 设备分析
- 输出
- 零代码研究工作流
- 影像质量和维护洞察
- 基础模型与智能体层
- 较新的路线图项目使用多模态模型生成报告、指导临床医生并监测运营。
- 模块
- uAI Insight 影像转报告智能体
- uAI Avatar 医疗助手
- 医院管理智能体
- uAI NEXUS 多模态基础模型
- 输出
- 结构化报告
- 自然语言工作流辅助
- 运营分析
- 服务与生命周期层
- 母集团的安装、维护、升级、培训和远程支持能力，为已部署系统提供运营外壳。
- 模块
- 安装与配置
- 硬件和软件升级
- 临床应用支持
- 远程培训与服务
- 输出
- 部署支持
- 生命周期维护
- 治理与市场准入层
- 许可和认证构成了部分信任外壳，但产品层面的可用性仍缺乏完整、一致的记录。
- 模块
- 已命名的 FDA 关联目录条目
- 各国特定的产品可用性限制
- 集团层面的 ISO 27001 / 27701 / 27017
- 产品层面的认证范围尽调
- 输出
- 监管市场准入
- 采购信任基线
- 各国可用性限制
5.3 已获许可的工作流工具与智能体路线图成熟度不一
最成熟的是具名监管关联产品：肋骨骨折分诊、颅内出血分诊和 uAI Portal 均有 FDA 关联条目。Physician AI Tools 估计 15 个获批产品，但资料池没有监管登记核实总数。RSNA 2025 的 uAI Insight、uAI Avatar 和医院管理智能体是从任务自动化走向人机协作的路线图，可信但不等于广泛临床可用。[CE003, CE006, CE007, CE008, CE009]
5.4 存在技术验证，但安全与实施尽调仍未完成
外部技术验证包括与 Massachusetts General Hospital 合作，利用美国以外数千名患者经验构建 COVID 期间影像算法；母集团还有 ISO 27001、ISO 27701、ISO 27017 和 NIST CSF 2.0 评估。RSNA 同时警告并非所有 AI 应用都在每国获批或可用；资料没有独立 UII 信任中心或状态页，母集团披露的软件验收周期也很长。[CE008, CE010, CE013, CE014]
5.5 展品
06客户
6.1 客户分为三条渠道，母集团生态仍居核心
公开细分为临床赋能、科研赋能和设备赋能，对应医院放射科和治疗科室、学术或临床研究用户，以及 United Imaging 装机基础。官方 FAQ 将 UII 描述为推进集团 AI 计划的 AI 决策支持子公司；客户触达和部署相当一部分似乎通过集团设备及医院渠道完成，而非直接软件销售。[CU001, CU002, CU003, CU012, CU016]
| 细分 | 买方 / 用户 / 付费方 | 用例 | 规模 | 收入 / 战略价值 | 缺口 |
|---|---|---|---|---|---|
| 临床赋能 | 医院放射科；临床医生使用，医院或医疗系统可能付费 | 临床影像工作流中的 AI 辅助诊断与报告 | 按收入计约占业务的 60-70%；主要部署在放射科 | 已披露的最大商业细分，也是最接近可重复临床工作流价值的部分 | 未披露付费机构数量、ASP 或续约情况 |
| 研究赋能 | 学术医疗中心与医生研究用户 | 支持研究工作流、模型开发与验证 | 按收入计约占业务的 20% | 带来 KOL 验证，并可为后续临床部署播种 | 未公开披露科研资助 / 研究用途与签约经常性收入之间的拆分 |
| 设备赋能 | United Imaging 设备团队、医疗机构部门和已安装扫描仪 | 将 AI 嵌入影像设备和性能增强工作流 | 按收入计约占业务的 10% | 将软件与硬件及既有工作流绑定，进一步提高切换成本 | 独立变现与捆绑附加率未披露 |
| 旗舰医院参考 | 已点名的三级医院、学术中心和跨境研究伙伴 | 联合开发、工作流数字化和机构级参考价值 | 已点名案例包括 MGH、Zhongshan、Renji 和 Peking University Health Science Center | 支撑市场进入与扩张可信度 | 各账户的生产状态和合同金额不同，且很少量化 |
各行综合公司、分析师和已点名参考来源；null 等价缺口表示保留的公开记录未披露客户经济性。
[CU001, CU002, CU003, CU006, CU007, CU008, CU009, CU010, CU016]UII 似乎先靠研究合作和标杆客户建立可引用性，再扩展到医院各类工作流。
这条路径反映的是保留的来源叙事，而非实测转化率或分阶段客户数。
[CU002, CU003, CU006, CU007, CU008, CU009, CU010, CU013, CU014, CU015]6.2 存在采用证据，但广度声明仍领先于经审计的运营细节
真实使用证据存在但不均衡：Massachusetts General Hospital 用于联合 AI 研究，Zhongshan Hospital 用于多场景 AI 智能体，Renji Hospital 用于 AI 放疗工作流。资料称截至 2024 年底有超过 100 个医疗 AI 产品和多项许可，第三方称在 3,000 多家医院部署超过 100 个 AI 应用；这支持商业广度，却不是经审计的活跃客户分母。[CU004, CU005, CU006, CU007, CU008, CU010, CU014]
| 指标 | 数值 | 日期 | 来源 | 置信度 | 含义 | 缺失分母 |
|---|---|---|---|---|---|---|
| 已推出的医疗 AI 产品 | >100 个医疗 AI 产品 | 2024 年末至 2025 年 3 月的引用 | Sina 分析师纪要；Yicai | 中 | 显示产品目录广泛，而非单点工具 | 其中有多少产品正在产生收入并被积极使用 |
| 监管 / 认证覆盖 | 12 个 NMPA III 类、21 个 NMPA II 类、13 个 CE、15 个 FDA | 2024 年末 | Sina 分析师纪要 | 中 | 表明其已准备好在多个市场开展受监管临床部署 | 哪些获批产品已形成实质商业化，哪些仍是展示资产 |
| 医院覆盖声明 | 全球超过 3,000 家医院部署了 100 多个 AI 应用 | 未注明日期的简介 | IntuitionLabs | 低 | 若准确，意味着已安装基础覆盖面显著 | 活跃付费站点、模块级使用情况及对该数量的独立审计 |
| 工作流套件覆盖 | uAI Clinical Portal 覆盖影像模态和疾病领域的 60 多个 AI 应用 | WHX 2026 | Hospitals Magazine / 公司联合发布内容 | 中 | 机构采用套件后，支持先落地再扩展 | 有多少医院在生产环境使用多个模块 |
该表区分目录广度与已验证的变现使用；当数量来自未经审计的简介或营销式会议报道时，置信度会降低。
[CU004, CU005, CU010, CU012]| 客户 | 细分 | 部署 / 用例 | 生产环境还是试点 | 结果 | 局限 |
|---|---|---|---|---|---|
| Massachusetts General Hospital | 学术医疗中心 / 研究 | 联合研究合作，利用 UII 对美国以外数千名患者的经验开发 X-ray AI 模型 | 研究合作；尚未证明进入商业生产 | 公开 IP 合作，以及与美国顶尖机构的已点名临床伙伴关系 | 未披露合同金额、续约或规模化部署数量 |
| Zhongshan Hospital | 中国顶级三级医院 | 正在联合开发并部署跨放射科、介入放射科、外科、客服、EMR 和质量控制管理等多场景医疗 AI 智能体 | 深度联合开发并部署 | 显示工作流已渗透多个部门，而非局限于一种模态 | 公司发布的案例，未提供用户数量或收入细节 |
| Renji Hospital | 医院放疗中心 | AI Smart Radiotherapy Center 使用 United Imaging 的云端智能中枢和 CT-linac 集成 | 工作流被描述为已运行 | 靶区勾画、治疗计划和质量控制可在数分钟内完成 | 生产经济性、席位数和续约条款未披露 |
| Peking University Health Science Center | 医科大学 / 医院网络 | 合作覆盖先进影像、智能介入放疗、AI 驱动的数据管理和急诊放疗 | 合作 / 部署范围未量化 | 支撑精准医疗与智慧医院场景的广度 | 该参考案例尚不足以证明已形成规模化付费生产 |
这是保留来源池中已点名参考案例的部分枚举；null 式缺口反映生产、合同和续约细节缺失。
[CU006, CU007, CU008, CU009, CU010, CU013, CU014]6.3 扩张逻辑合理，但持久性证据仍缺失
扩张靠工作流深度推进。WHX 2026 称 uAI Clinical Portal 覆盖 60 多个应用，案例延伸至手术、EMR、质控、放疗规划和运营分析，像是医院科室内的落地扩展。但没有披露 NRR、GRR、流失、续约、合同期限或直接付费站点数，也很少量化授权模块、使用频率或从试点到软件标准的转化。[CU007, CU008, CU009, CU010, CU013]
6.4 客户集中风险更多来自渠道依赖，而非单一医院
主要集中风险来自母集团生态的商业角色，而非单一医院。UII 的软件强化 United Imaging 硬件和工作流方案；第一财经和 Multiples.vc 更多提及母集团融资而非客户变现。Reuters 称管理层因技术尚不够成熟而抵制极端 AI 推广。技术尚未成熟不代表需求疲弱，但意味着商业化曲线可能更克制。披露直接与捆绑销售、头部客户和续约前，收入持久性仍不透明且可能与集团采购关系交织。[CU011, CU012, CU015, CU016]
6.5 展品
07风险
7.1 风险排序图景
最高严重度风险不是笼统 AI 不确定性，而是 UII 承认临床部署应谨慎，因为技术可能产生有害副作用。公司同时营销广泛智能体、质控工具和工作流软件，但公开证据没有逐模块商业化、获批和事故图谱。其他风险包括依赖集团渠道、硬件嵌入和数据访问，以及缺少支撑最后估值的独立收入和利润率基础；营运资金、分销控制和海外审批摩擦相对更可监测。[CR002, CR003, CR004, CR006, CR011, CR015]
最高优先级风险集中在临床 AI 推进和集团依赖；营运资金与渠道风险同样重要，但更容易通过运营监测。
点位是定性且基于来源的判断；矩阵表达相对优先级，而非统计概率模型。
[CR002, CR004, CR006, CR007, CR008, CR010, CR015]7.2 监管、法律与模型安全风险
监管和法律风险在于产品面扩张快于各模块获批、可报销和生产安全的公开证明。RSNA 明确称并非所有展示应用都带 CE 标志或 FDA 批准；母集团还面临审批壁垒、知识产权争议和技术秘密泄露。关键问题是 UII 是否有逐产品证据、上市后监测和知识产权规范，能在不发生监管或质量重置的情况下扩张。[CR002, CR003, CR004, CR005, CR007, CR016]
| 风险 | 司法辖区 / 状态 | 可能性 | 严重性 | 缓释措施 | 剩余暴露 | 尽调路径 |
|---|---|---|---|---|---|---|
| 医疗 AI 获批错配 | 全球；RSNA 2025 披露称，并非所有展示的 AI 应用都已取得 CE 标志或 FDA 许可；第三方市场数据则引用了有实质规模但并不完整的 FDA/CE/NMPA 获批情况。 | 中高 | 高 | 既有获批基础，加上刻意放缓的推出节奏 | 新智能体和工作流功能可能按地域超出已获批适应症 | 将每个在售模块与其许可、适应症和国家可用性逐一对应 |
| 海外获批与市场进入拖累 | 母公司年报称，海外主营业务收入达到 3.393 billion yuan，占主营业务收入的 25.79%；但也警告，审批、贸易摩擦和不成熟的海外渠道可能拖慢扩张。 | 中 | 高 | 建设全球团队、设立子公司并推进产学研医合作 | 注册延迟或政策变化仍可能拖慢规模化推出 | 审阅审批排队、监管往来函件及逐国发布门槛 |
| IP 侵权或技术秘密泄露 | 母公司年报明确警告，关键核心技术泄露将损害研发效率和盈利能力 | 中 | 中高 | 专利布局、保密协议和正式 IP 保护体系 | 若控制失效，嵌入式模型、数据和工作流诀窍仍难以防守 | 要求提供专利图谱、既往争议、员工离职控制和伙伴 IP 条款 |
按严重性排序的部分公开登记表；各行结合公司披露与当前面向市场的证据，并将模块级获批映射留作尽调缺口。
[CR002, CR004, CR005, CR007, CR016]7.3 运营与合作伙伴执行风险
运营风险因 UII 同时覆盖扫描仪运行、质控、报告工作流和医院运营而放大，采购延迟、分销执行失误、应收拖延或质量故障都可能拖慢商业化。母集团强调供应商审计、安全库存、保密控制、分销商培训和回款纪律；公开采用证据仍偏向明星站点和演示，尽调应验证旗舰案例能否推广为可靠日常部署。[CR006, CR007, CR008, CR009, CR010, CR012, CR013]
| 失效模式 | 可能性 | 严重性 | 缓释成熟度 | 剩余暴露 | 未解决缺口 |
|---|---|---|---|---|---|
| 生成式 AI 过早进入临床工作流 | 高 | 高 | 中；管理层刻意放慢推出，并明确拒绝“极端”的采用压力 | 诊断或工作流错误会落在高风险医疗场景中 | 需要模块级 QA 阈值、覆盖规则和上市后事件率 |
| 报告与扫描仪运营对工作流质量和正常运行时间的依赖 | 中 | 高 | 中；UII 将 uQP、医院管理工具和 uMetaGenesis 定位为质量控制与正常运行时间的缓释措施 | 公开证据未量化正常运行时间、误报率或运营节省 | 按站点索取 SLA 历史、停机日志和质量控制结果基线 |
| 经销商与渠道控制失效 | 中 | 中高 | 中高；母公司提到经销商管理系统、销售培训、合规指引和年度评估 | 分销强度仍使增长暴露于合规和回款失败 | 审阅经销商集中度、流失、回款历史和执法事件 |
| 应收账款与采购周期延误 | 中 | 中高 | 中；管理层描述了信用审查、回款监督、供应商审计、安全库存和保密控制 | 医院预算节奏与客户信用恶化仍是外部约束 | 按地区索取子公司 AR 账龄、DSO、库存周转和积压转化 |
指定来源池未提供安全专项公开事件证据，因此本表记录来源披露的运营控制和暴露的失效面。
[CR002, CR003, CR006, CR008, CR009, CR013]7.4 集团依赖、资本风险与论点破坏因素
结构性风险是 UII 更像 United Imaging 设备战略中的 AI 赋能部门，而非透明独立软件公司。唯一公开估值是 June 2025 $1.4 billion A 轮，没有独立收入、利润率或现金桥接；若审批落后、旗舰医院无法转化为付费群组、转移定价或渠道依赖限制独立经济性，或回款和海外准入拖慢下一轮融资，投资论点会迅速失效。[CR001, CR010, CR011, CR012, CR014, CR015]
| 依赖项 | 交易对手 | 角色 | 集中度 | 失效情景 | 严重性 | 缓释措施 | 剩余暴露 |
|---|---|---|---|---|---|---|---|
| 对母公司硬件、数据和渠道的依赖 | United Imaging 集团 | 已安装基础接入、硬件嵌入、数据获取和市场路径 | 集团嵌入式 | UII 无法证明独立经济性；若集团优先事项变化，也会失去议价能力 | 高 | 软硬件协同当前带来分发和产品嵌入 | 独立议价能力与转移定价透明度仍未得到证明 |
| 对旗舰医院验证的依赖 | MGH、Zhongshan Hospital、Renji Hospital 及类似标杆机构 | 临床证明、联合开发和参考部署 | 标杆站点偏斜 | 参考站点不能泛化为广泛付费使用或持久续约 | 中高 | 覆盖不同地域和工作流的多家已点名机构 | 未公开披露留存队列、付费站点数量或大客户集中度数据 |
| 唯一已披露的估值锚点 | 2025 年 6 月 Series A 投资者银团 | 资本与价格发现 | 一轮公开融资 | 若独立经济性仍未披露，下一轮融资会重置价格 | 高 | 近期 1.39 亿美元融资及战略资本参与 | 公开证据仍缺乏收入、利润率和现金转化对该估值的支撑 |
剩余暴露更多取决于公开证据在多大程度上无法将 UII 的经济性与更广泛集团及旗舰伙伴区分开，而非这些依赖是否存在。
[CR001, CR010, CR011, CR012, CR014, CR015]08估值
8.1 投资判断与价格纪律
本章结论是 **继续研究**。问题不在于产品可信度缺少证据，而在于公开材料对估值的支撑只到上一轮融资标题。Multiples 记录了一笔 June 2025 A 轮融资：估值 $1.4 billion，募资 $139 million；FLCube 则印证 RMB 1 billion 的融资金额及投资者兴趣。但两者都没有披露独立收入、毛利率、留存率或付费装机转化率。Preqin 将同一笔 CNY 1 billion 融资描述为 October 2025 的风险投资，令融资时间和投资者名单更加模糊。因此，投资者只能确认公司融到资金、技术覆盖面广，仍没有足够证据把上一轮估值换算成站得住脚的经营倍数，也无法论证按当前估值入场的目标回报。[CV001, CV002, CV003, CV013]
| 建议 | 置信度 | 风险评级 | 估值立场 | 决策含义 |
|---|---|---|---|---|
| research-more | 中 | 高 | 偏高 | 在获得独立 KPI 和股权表披露前，不要按高于上一轮的价格做投资判断。 |
该摘要判断源自公开融资、产品和风险证据；立场明确对价格敏感，并反映独立公司经济性缺失。
[CV001, CV003, CV011, CV012, CV013]证据支持其战略质量，但价格信号已经跑在公开经济数据之前。
| 节点 / 连接 | 节点 / 起点 | 终点 | 说明 |
|---|---|---|---|
| 节点 1 | 产品与审批广度 [scale] | 截至 2024 年末已有 100 多个产品，且跨司法辖区审批仍在增加。 | |
| 节点 2 | 临床与技术验证 [validation] | 对外合作历史及公司自称的报告智能体表现，显示其具备真实能力。 | |
| 节点 3 | 最近一轮融资存在 [financing] | 公开数据库和报道指向一笔 2025 年约 $139M / RMB1B 的融资，估值为 $1.4B。 | |
| 节点 4 | 融资轮次结构模糊 [structure] | 公开记录对时间存在分歧，并显示关联方参与程度不低。 | |
| 节点 5 | 独立经济性仍不透明 [economics] | 没有公开收入、利润率、留存或股权结构表条款来支撑明确的经营倍数。 | |
| 节点 6 | 继续研究 / 估值偏高 [recommendation] | 在把上行空间计入投资判断前，应等待可审计 KPI，或等待明显更好的入场条款。 | |
| 连接 1 | 产品与审批广度 [scale] | 临床与技术验证 [validation] | Quality signals |
| 连接 2 | 临床与技术验证 [validation] | 最近一轮融资存在 [financing] | Supports fundability |
| 连接 3 | 最近一轮融资存在 [financing] | 融资轮次结构模糊 [structure] | But round signal is not clean |
| 连接 4 | 融资轮次结构模糊 [structure] | 独立经济性仍不透明 [economics] | Missing terms and metrics |
| 连接 5 | 独立经济性仍不透明 [economics] | 继续研究 / 估值偏高 [recommendation] | Prevents conviction at price |
8.2 融资背景与可比锚点
融资记录更像有生态赞助的战略轮，而非独立基准验证的市场价格。第一财经称 United Imaging Healthcare 以 RMB 70 million 取得 0.70% 新股、累计 0.9849%，United Imaging Group 和 Shanghai Lianhe 也参与；分析师报告称业务以临床赋能为主，Multiples 将其放在约 $1.3 billion–$1.4 billion AI 医疗可比公司附近。没有独立财务数据时，这些可比公司只是方向性的情绪锚点。[CV001, CV004, CV005, CV006, CV013, CV014]
| 论点 | 方向 | 哪些信息会改变判断 |
|---|---|---|
| UII 展现了真实的产品广度，并在 NMPA、CE 和 FDA 路径上拥有广泛认证基础。 | 支持 | 验证产品目录中有多少在活跃使用、付费并实现账户级续约 |
| United Imaging 生态支持提升分发覆盖和战略韧性。 | 支持 | 确认关联方定价、IP 所有权，以及渠道接入是合同约定还是酌情提供 |
| 上一轮融资证明外部投资者愿意按规模为该资产提供资金。 | 支持 | 核对公开记录在融资时间、参与者构成和投后条款上的冲突 |
| 公开来源未披露独立收入、毛利率或留存，因此 $1.4B 估值无法与经营倍数挂钩 | 反对 | 获取覆盖收入、利润率和队列表现的经审计子公司财务或董事会级 KPI 包 |
| 关联方和国资背景资本的规模似乎足以模糊该轮融资的市场出清信号。 | 反对 | 审阅股权结构表、清算优先权，以及授予母公司或关联投资者的任何战略权利 |
| 由于市场进入周期长、现有企业可能施压定价，商业化风险仍高。 | 反对 | 展示多地区付费部署，并证明软件变现并非只是随硬件落地捆绑销售 |
各论点综合保留来源，并被写成尽调测试而非独立事实；每一行都点明推动建议变化所需的具体证据。
[CV001, CV003, CV004, CV005, CV007, CV008, CV012, CV013]8.3 情景框架与下行触发因素
区间应理解为围绕上一轮的决策带，而非精确 DCF。乐观情景要求变现装机基础并形成高端软件经济性；基准情景假设质量真实但变现部分捆绑母集团；悲观情景假设披露追不上价格且市场准入更慢。年报还警告海外审批周期长，GE Healthcare、Siemens Healthineers 和 Philips 可能挤压份额和定价。[CV007, CV008, CV010, CV011, CV012, CV013]
| 情景 | 假设 | 估值 / 回报逻辑 | 关键风险 | 概率信号 |
|---|---|---|---|---|
| 乐观 | 付费采用在已安装基础上证明具有黏性，更多获批转化为可报销工作流，战略渠道加速国际化推出 | 只有审计证据证明可重复的软件经济性，而非战略稀缺性，才能支撑此前 14 亿美元的估值 | 执行仍取决于证明独立利润率和可出口的监管转化能力 | 需要经审计的 KPI 披露，以及软件变现独立于捆绑硬件销售的证据 |
| 基准 | 产品和监管广度真实存在，但变现仍有一部分与母公司设备捆绑，融资条款也只部分可见 | 不支持任何内在价值区间；要求入场价低于此前估值，或取得里程碑、优先权和信息权保护 | 投资者可能在收入质量尚未显现前，为平台期权价值支付过高价格 | 符合当前证据组合：真实的牵引信号、尚未解决的经济性，以及相互冲突的融资记录。 |
| 悲观 | 部署广度未转化为付费使用深度，按地区划分的获批范围比营销暗示的更窄，下一轮融资在更弱市场中进行 | 低于此前估值的大幅重置是可能的，但公开证据不足以支持精确的下行底线 | 若战略内部人士仍是主要资金来源，下一轮下行风险上升 | 收入、股权结构表或客户转化持续不透明即可触发 |
这些是锚定最近一次披露私募融资的条件性决策规则，不是预测。由于缺乏 UII 独立财务及证券层面的输入，未赋予数值内在价值区间或概率。
[CV001, CV004, CV006, CV007, CV008, CV011, CV012, CV013]8.4 最终尽调要求与论点破坏因素
建议只有在尽调填补三项缺口后才会改变：独立收入、毛利率和付费客户群；2025 年融资的股权表与优先权条款；以及独立软件预算与母集团硬件导流的采用拆分。若能证明广泛部署和监管广度转化为可重复的软件经济性，当前价格可能站得住；否则估值偏高，容易出现降价轮或平轮。[CV006, CV007, CV009, CV011, CV012, CV013]
8.5 展品
免责声明
本报告是基于公开证据的尽调快照，不构成投资建议。重要的财务、法律、技术和合同事实仍未公开，任何投资决策前都应直接向管理层及一手文件核实。
证据索引
| 编号 | 陈述 | 可信度 | 来源 |
|---|---|---|---|
| CO001 | United Imaging Intelligence was founded in 2017. | 中 | SO003, SO008 |
| CO002 | United Imaging Intelligence is headquartered in Shanghai, China. | 中 | SO003, SO008 |
| CO003 | United Imaging Intelligence is the medical-artificial-intelligence subsidiary within United Imaging Group. | 高 | SO003, SO005, SO006, SO007, SO008 |
| CO004 | Multiples reports that Professor Shen Dinggang leads aspects of UII's data-driven algorithm and clinical-application work. | 中 | SO008 |
| CO005 | CMB estimated UII's revenue mix at roughly 60%-70% clinical empowerment, 20% research empowerment, and 10% equipment empowerment. | 中 | SO007 |
| CO006 | CMB reported that UII had launched more than 100 medical-AI products by the end of 2024. | 中 | SO007 |
| CO007 | CMB reported that UII held 12 NMPA Class III, 21 NMPA Class II, 13 CE, and 15 FDA certifications at the end of 2024. | 中 | SO007 |
| CO008 | Parent-funded R&D and UII's integration across United Imaging product lines indicate material dependence on group resources and distribution. | 中 | SO001, SO007 |
| CO009 | In September 2020, UII America CEO Terrence Chen described a joint COVID-19 imaging research collaboration between United Imaging teams and Massachusetts General Hospital. | 中 | SO004 |
| CO010 | Multiples reports that UII raised a $139 million Series A in June 2025 led by E Fund and Shangguo Investment Management. | 中 | SO008 |
| CO011 | Multiples reports that UII was valued at $1.4 billion in its June 2025 Series A. | 中 | SO008 |
| CO012 | A December 2024 report said United Imaging Healthcare planned to invest RMB 28.4872 million for 0.2849% of UII after a capital increase at a RMB 9 billion pre-investment valuation. | 中 | SO002 |
| CO013 | UII reported RMB 166 million of revenue and an RMB 82.9218 million net loss for the first nine months of 2024. | 中 | SO002 |
| CO014 | UII reported RMB 254 million of revenue and an RMB 136 million net loss for 2023. | 中 | SO002 |
| CO015 | At RSNA 2025, UII claimed its chest-CT reporting agent could detect 73 thoracic diseases at an average AUC of 95%. | 中 | SO005 |
| CO016 | At WHX 2026, a company-issued report described UII's uAI Clinical Portal as containing more than 60 applications across imaging modalities and disease areas. | 中 | SO006 |
| CM001 | UII's brochure positions the company as a medical-AI provider that enables smart equipment, supports biomedical research, and covers workflow from screening and diagnosis through treatment and follow-up. | 中 | SM001 |
| CM002 | UII's brochure says more than 40 AI technologies empower all-modalities medical equipment and radiotherapy equipment. | 中 | SM001 |
| CM003 | UII's brochure says 50-plus AI-assisted applications are integrated across diseases, clinical scenarios, and all medical imaging modalities from screening and diagnosis to treatment and follow-up. | 中 | SM001 |
| CM004 | A Sina Finance repost of a sell-side note says UII's revenue mix is roughly 60-70% Clinical Empowerment, 20% Research Empowerment, and 10% Equipment Empowerment. | 中 | SM003 |
| CM005 | The same sell-side note says UII's clinical-empowerment segment is primarily deployed in radiology departments. | 中 | SM003 |
| CM006 | The sell-side note says that by the end of 2024 UII had launched more than 100 medical AI products and held 12 NMPA Class III, 21 NMPA Class II, 13 CE, and 15 FDA certifications. | 中 | SM003 |
| CM007 | United Imaging Healthcare's 2025 annual report says China's large-scale medical-equipment renewal policy released demand for high-end imaging, radiotherapy, and primary-level diagnostic-capacity building and that industry scale recovered versus the prior year. | 中 | SM002 |
| CM008 | The sell-side note argues that policy-driven equipment renewals and rising clinical AI adoption should support United Imaging's equipment-plus-AI growth thesis. | 中 | SM003 |
| CM009 | UII's quality-control workflow describes a model in which a main or tertiary hospital supervises image quality across satellite and primary or secondary hospitals. | 中 | SM001 |
| CM010 | A United Imaging release about the Massachusetts General Hospital collaboration says UII adapted experience from thousands of patients outside the U.S. and then refined X-ray models with U.S. patients, implying that local clinical collaboration is part of adoption and validation. | 中 | SM005 |
| CM011 | United Imaging's U.S. market-debut release says UII was created to embed AI in UIH's core software across all modalities and push AI further up the imaging chain. | 中 | SM006 |
| CM012 | UII's RSNA 2025 release says its AI agents span diagnostic imaging, surgical care, patient services, hospital operations, and clinical research across the care pathway. | 中 | SM007 |
| CM013 | Hospitals Magazine's WHX 2026 coverage says UII highlighted a clinical portal with over 60 AI applications, a research portal, a quality-control portal, and an operations-insight platform. | 中 | SM008 |
| CM014 | An AI-generated IntuitionLabs profile claims UII has deployed more than 100 AI applications across more than 3,000 hospitals globally, but that source also warns it may contain errors and is not corroborated elsewhere in this pool. | 低 | SM004 |
| CM015 | United Imaging's U.S. market-debut release says more than 2,700 hospitals worldwide were using UIH products at the time, supporting the idea that UII can piggyback a meaningful installed-base channel rather than selling only stand-alone software. | 中 | SM006 |
| CM016 | The public source pool provides workflow, product, certification, and deployment proxies but does not disclose UII's stand-alone software revenue, pricing, paid-site counts, or monetized attach rate, so a reliable dollar TAM, SAM, or SOM cannot be isolated from these materials. | 中 | SM001, SM002, SM003, SM004, SM008 |
| CP001 | Public profiles in the assigned pool consistently describe UII as the AI subsidiary of United Imaging Group founded in 2017. | 中 | SP001, SP002, SP003 |
| CP002 | Assigned sources describe UII's scope as spanning imaging diagnosis, treatment planning, research, and hospital-management workflows across multiple imaging modalities. | 中 | SP001, SP003, SP004 |
| CP003 | Health AI Register lists UII applications across CT, PET, cardiac, and neuro workflows, including rib-fracture detection, pulmonary-embolism triage, CCTA, CT-FFR, calcium scoring, whole-body uptake detection, and neuro triage. | 中 | SP002 |
| CP004 | UII's RSNA 2024 materials frame its differentiation around foundation models, medical LLMs, and assistant-style workflow products rather than only single algorithms. | 中 | SP004 |
| CP005 | UII's RSNA 2025 materials extend that positioning into imaging-to-report, ultrasound, and hospital-management AI agents. | 中 | SP006 |
| CP006 | Independent directories in the assigned pool do not converge on one dominant rival set: Dealroom highlights Pixyl, Quibim, Nucs AI, and Radiobotics, while IntuitionLabs lists MaxQ AI, JLK, Neurocareai, and Heuron. | 中 | SP001, SP003 |
| CP007 | Because the recurring independent peer lists are dominated by specialist software vendors, UII appears to compete against clusters of focused imaging-AI tools more than against a single obvious full-platform software benchmark. | 中 | SP001, SP003 |
| CP008 | A parent-linked analyst note says UII had launched more than 100 AI products by the end of 2024 and split its business across clinical empowerment, research empowerment, and equipment empowerment. | 中 | SP007 |
| CP009 | The same analyst note says UII's AI applications had been fully adopted across United Imaging's entire product lines. | 中 | SP007 |
| CP010 | Yicai reported in March 2026 that United Imaging Healthcare said its investment in UII was intended to strengthen product intelligence and enhance competitiveness in the high-end market. | 中 | SP008 |
| CP011 | UII's public route to credibility includes academic and hospital collaborations such as its Massachusetts General Hospital research partnership. | 中 | SP005 |
| CP012 | Across the assigned public sources reviewed for this chapter, UII's standalone software pricing, contract structure, and named win-rate versus competitors are not disclosed. | 中 | SP001, SP002, SP003, SP004, SP005, SP006, SP007, SP008 |
| CP013 | The moat case supported by the assigned pool rests mainly on scope breadth and parent-linked distribution rather than independently benchmarked head-to-head competitive proof. | 中 | SP001, SP003, SP007, SP008 |
| CP014 | Because UII markets reporting, research, and quality-management workflow software, status-quo manual processes and hospital internal build are meaningful substitute competition even when named vendors are missing from the assigned pool. | 中 | SP004, SP005, SP006 |
| CI001 | United Imaging said it invested $45 million to establish an artificial-intelligence subsidiary. | 中 | SI002 |
| CI002 | United Imaging described its imaging products, intelligent imaging cloud, and imaging centers as data sources and deployment channels for UII algorithms. | 中 | SI002 |
| CI003 | Yicai reported that United Imaging Healthcare intended to invest RMB70 million in UII for 0.70% post-transaction ownership. | 中 | SI003 |
| CI004 | Yicai reported that United Imaging Healthcare's cumulative UII holding would reach 0.9849% after the transaction. | 中 | SI003 |
| CI005 | Yicai reported that United Imaging Group and Shanghai Lianhe also participated in the capital increase with post-transaction holdings of 2% and 1.7901%, respectively. | 中 | SI003 |
| CI006 | A Sina-hosted analyst note attributed approximately 60-70% of UII business by revenue to clinical empowerment, about 20% to research empowerment, and about 10% to equipment empowerment. | 中 | SI008 |
| CI007 | Yicai and the Sina-hosted analyst note each reported that UII had launched more than 100 medical-AI products by their respective reporting periods. | 中 | SI003, SI008 |
| CI008 | The Sina-hosted analyst note said UII AI applications had been adopted across United Imaging's product lines. | 中 | SI008 |
| CI009 | IntuitionLabs claimed that UII had deployed more than 100 AI applications across more than 3,000 hospitals, while warning that its AI-generated profile may contain errors. | 低 | SI005 |
| CI010 | United Imaging's 2020 collaboration announcement said UII software drew on experience with thousands of patients outside the United States. | 中 | SI006 |
| CI011 | Reuters reported that UII's co-CEO resisted an aggressive AI rollout because the technology remained insufficiently mature, and Yahoo Finance carried the same syndicated report. | 中 | SI001, SI004 |
| CI012 | Baidu describes UII as a strategic United Imaging Group subsidiary that uses the group's software, hardware, and resource advantages. | 低 | SI007 |
| CI013 | The disclosed founding investment and later related-party capital increase demonstrate access to aligned capital but do not establish UII's current cash balance or runway. | 中 | SI002, SI003 |
| CI014 | Across the eight retained chapter sources, no source disclosed UII standalone revenue, ARR, realized pricing, gross margin, CAC or payback, cash burn, runway, or debt obligations. | 中 | SI001, SI002, SI003, SI004, SI005, SI006, SI007, SI008 |
| CI015 | Public evidence supports a parent-enabled three-lane commercialization model, but it does not show how deployments convert into recognized standalone revenue or gross profit. | 中 | SI002, SI006, SI008 |
| CE001 | United Imaging Intelligence is described as a 2017 AI-focused subsidiary of the United Imaging group that builds medical-imaging and workflow software. | 高 | SE002, SE003, SE005 |
| CE002 | Public descriptions place UII's product scope across screening, triage, image analysis, treatment planning, research, and hospital operations rather than a single algorithm niche. | 高 | SE002, SE003, SE005, SE007 |
| CE003 | Independent directories in the assigned pool list named, FDA-linked products spanning 2021 to 2024, including uAI EasyTriage-Rib, uMR 680, uAI Portal, and uAI Easy Triage ICH. | 中 | SE002, SE006 |
| CE004 | uAI Portal is presented as a CT angiography analysis workflow with AI-based segmentation for lower-extremity, head-and-neck, coronary, pulmonary, and aortic studies. | 中 | SE006 |
| CE005 | UII's named triage tools are framed as workflow-prioritization and notification products that assist radiologists without replacing diagnosis. | 中 | SE002, SE006 |
| CE006 | Third-party profiles describe UII as having over 10 AI platforms, more than 100 AI applications, and a uAI Clinical Portal with over 60 applications. | 中 | SE002, SE007 |
| CE007 | UII's current roadmap extends from application software into multimodal foundation models and agentic workflows such as uAI Insight, uAI Avatar, and hospital-management agents. | 高 | SE005, SE007 |
| CE008 | The RSNA 2025 showcase was ahead of broad documented clearance because the release says featured products may not be available in all countries and not all presented AI applications are CE-marked or FDA-cleared. | 中 | SE005 |
| CE009 | UII claims broad deployment, with over 100 AI applications across more than 3,000 hospitals globally and products deployed in thousands of hospitals. | 中 | SE002, SE003 |
| CE010 | UII has documented external research validation through a Massachusetts General Hospital collaboration that used experience from thousands of patients outside the United States to develop COVID-era imaging algorithms. | 高 | SE002, SE004 |
| CE011 | UII's differentiation appears to come from tight integration with United Imaging Healthcare hardware, cloud platforms, imaging centers, and installed systems rather than from standalone software distribution alone. | 中 | SE007, SE008 |
| CE012 | United Imaging Healthcare says it uses shared hardware and software R&D platforms plus a common underlying architecture across product lines, which should accelerate multi-modality integration and iteration for embedded AI products. | 中 | SE001 |
| CE013 | Group-level trust controls are visible at United Imaging Healthcare through ISO 27001, ISO 27701, ISO 27017, and an active NIST CSF 2.0 assessment at United Imaging America. | 中 | SE001 |
| CE014 | The parent reported that software product revenue fell 34.49% in the reporting period because software projects had long acceptance cycles, signaling implementation friction that could also matter for AI-software rollout. | 中 | SE001 |
| CU001 | United Imaging Intelligence was established in December 2017 to develop, produce, and sell AI-driven decision support products from a Shanghai base with additional R&D centers in Beijing, Wuhan, Chengdu, and the U.S. | 中 | SU001 |
| CU002 | An analyst note says UII's business mix is split across clinical empowerment at roughly 60-70% of revenue, research empowerment at roughly 20%, and equipment empowerment at roughly 10%. | 中 | SU006 |
| CU003 | The same analyst note says clinical empowerment is primarily deployed in radiology departments, research empowerment supports physicians in research, and equipment empowerment enables intelligent upgrades and performance enhancements of medical devices. | 中 | SU006 |
| CU004 | By the end of 2024, UII had launched over 100 medical AI products and held 12 NMPA Class III certificates, 21 NMPA Class II certificates, 13 CE certifications, and 15 FDA certifications. | 中 | SU006 |
| CU005 | A third-party directory profile says UII has deployed over 100 AI applications across more than 3,000 hospitals globally, but the page is AI-generated and not independently audited. | 低 | SU002 |
| CU006 | United Imaging's U.S. and Shanghai AI teams established a joint research collaboration with Massachusetts General Hospital to develop AI algorithms for COVID-19-related X-ray use cases. | 中 | SU003 |
| CU007 | WHX 2026 coverage said Zhongshan Hospital was co-developing and deploying multi-scenario medical AI agents with United Imaging across radiology, interventional radiology, surgery, customer service, EMR, and quality control management. | 中 | SU005 |
| CU008 | The same WHX 2026 coverage said Renji Hospital's AI Smart Radiotherapy Center uses United Imaging's cloud-based intelligent hub to digitize the radiotherapy workflow and complete contouring, planning, and quality control within minutes. | 中 | SU005 |
| CU009 | WHX 2026 coverage said Peking University Health Science Center was partnering with United Imaging across advanced imaging, intelligent interventional radiotherapy, AI-powered data management, and emergency radiotherapy. | 中 | SU005 |
| CU010 | WHX 2026 coverage said UII's uAI Clinical Portal featured over 60 AI applications across imaging modalities and disease areas. | 中 | SU005 |
| CU011 | Reuters reported that co-CEO Zhou Xiang said UII was not undertaking an extreme AI rollout because the technology remained insufficiently mature for medicine. | 中 | SU008 |
| CU012 | Yicai reported that UIH's cumulative shareholding in UII would reach only 0.9849% after its March 2025 related-party capital increase. | 中 | SU007 |
| CU013 | The retained sources do not disclose UII's NRR, GRR, churn, renewal schedule, contract length, or direct paid-institution count. | 中 | SU001, SU002, SU005, SU006, SU007, SU008, SU010 |
| CU014 | UII America's Boston team won the fastMRI challenge organized by Facebook AI Research and NYU School of Medicine, which signals research-community credibility rather than recurring customer adoption. | 中 | SU009 |
| CU015 | Multiples.vc records United Imaging's June 20 2025 participation in UII's $139M Series A at a $1.4B valuation, reinforcing that public market databases surface financing more readily than customer monetization. | 中 | SU007, SU010 |
| CU016 | The official FAQ frames UII as a group subsidiary providing AI-powered solutions and technical services that advance United Imaging's broader artificial-intelligence initiatives. | 中 | SU001 |
| CR001 | The parent's 2025 annual report identifies Shanghai United Imaging Intelligence Co., Ltd. as an enterprise controlled by the ultimate controlling person, so UII sits inside the same control structure rather than as an arms-length vendor. | 中 | SR003 |
| CR002 | On 2026-07-20, co-CEO Zhou Xiang said UII was resisting aggressive AI rollout because engineers warned that the technology remained insufficiently mature and carried potential side effects. | 高 | SR001, SR002 |
| CR003 | Zhou also said that in medicine the first-mover advantage is less drastic than in other fields, explicitly tying deployment pace to patient-harm risk if AI makes errors. | 高 | SR001, SR002 |
| CR004 | UII's RSNA 2025 materials said not all showcased AI applications are CE-marked or FDA-cleared, so marketed demos still exceed the fully cleared subset. | 中 | SR005 |
| CR005 | multiples.vc reported that as of July 2025 UII had 31 CE-marked AI applications, 15 FDA clearances, 15 Class III NMPA approvals, and over 60 AI applications in market-facing platforms. | 中 | SR007 |
| CR006 | The parent annual report said distribution revenue was 8.41 billion yuan, or 63.91% of main-business revenue, and warned that distributor compliance failures, disputes, or weak management could hurt growth. | 中 | SR003 |
| CR007 | The same annual report said overseas main-business revenue was 3.393 billion yuan, up 52.81% year over year and 25.79% of main-business revenue, while warning that approvals, trade friction, and immature overseas channels could disrupt expansion. | 中 | SR003 |
| CR008 | The parent annual report said accounts receivable are a significant proportion of current assets and that weaker customer finances could impair future operations and debt-repayment capacity. | 中 | SR003 |
| CR009 | The parent annual report describes supplier audits, elimination mechanisms, safety stock, and confidentiality agreements as key controls, implying procurement continuity and technical-information leakage remain active operational risks. | 中 | SR003 |
| CR010 | United Imaging's 2020 MGH announcement said its AI software was built from experience with thousands of patients outside the U.S. and that all collaboration IP would be public, showing UII relies on flagship institutions and externally visible collaborations to validate workflow claims. | 中 | SR004 |
| CR011 | multiples.vc lists UII at a $1.4 billion valuation after a $139 million June 2025 Series A led by E Fund and Shangguo Investment Management. | 中 | SR007 |
| CR012 | Hospitals Magazine reported that Zhongshan Hospital was co-developing and deploying multi-scenario medical AI agents with United Imaging across radiology, surgery, customer service, EMR, and quality control management. | 中 | SR006 |
| CR013 | At WHX 2026, UII said uMetaGenesis turns equipment operational data into actionable real-time insights that aim to minimize unplanned scanner downtime, indicating execution risk spans hospital operations as well as diagnostic accuracy. | 中 | SR006 |
| CR014 | Huatai's note said end-2024 UII revenue mix was roughly 60-70% clinical empowerment, about 20% research empowerment, and about 10% equipment empowerment, reinforcing that equipment-embedded AI remains a meaningful commercial dependency. | 中 | SR008 |
| CR015 | Official company materials consistently frame UII as the AI-focused subsidiary within United Imaging's broader group rather than as a standalone go-to-market stack. | 高 | SR003, SR004, SR005 |
| CR016 | The parent annual report warns that infringement of key core technologies or leakage of technical secrets would reduce R&D effectiveness and profitability, with patents and confidentiality agreements as the stated mitigation. | 中 | SR003 |
| CV001 | Multiples lists United Imaging Intelligence at a $1.4 billion valuation based on a June 2025 Series A and says the company has raised $139 million across one funding round. | 中 | SV003 |
| CV002 | FLCube reports that United Imaging Intelligence raised RMB 1 billion (about $139 million) in a Series A round co-led by E Fund Management and SIG Property Management, with participation from Shanghai Alliance Investment, Sun Rock Capital, Suzhou Capital Group, Tsing Song Capital, and United Imaging. | 中 | SV002 |
| CV003 | Preqin instead describes the same CNY 1 billion financing as October 2025 venture funding from Shanghai United Imaging Healthcare, United Imaging Group, and Shanghai Alliance Investment, leaving public timing and participant details inconsistent. | 中 | SV001 |
| CV004 | Yicai reports that United Imaging Healthcare committed RMB 70 million for 0.70% of new equity in United Imaging Intelligence and would hold 0.9849% cumulatively after the capital increase. | 中 | SV008 |
| CV005 | The same Yicai report says United Imaging Group and Shanghai Lianhe joined the financing with 2% and 1.7901% shareholding ratios respectively, implying that related-party and state-linked capital were material to the round structure. | 中 | SV008 |
| CV006 | A Sina Finance analyst report says UII's business mix at end-2024 was roughly 60-70% clinical empowerment revenue, about 20% research empowerment, and about 10% equipment empowerment. | 中 | SV004 |
| CV007 | The same Sina report says that by end-2024 UII had launched more than 100 medical AI products and held 12 NMPA Class III certificates, 21 NMPA Class II certificates, 13 CE certifications, and 15 FDA certifications. | 中 | SV004 |
| CV008 | Multiples says that as of July 2025 UII had 31 CE-marked medical AI applications, 15 FDA clearances, and 15 Class III NMPA approvals. | 中 | SV003 |
| CV009 | United Imaging's 2020 Massachusetts General Hospital press release says the company had already built AI software from experience with thousands of patients outside the United States and entered a joint research collaboration with MGH. | 中 | SV005 |
| CV010 | United Imaging's RSNA 2025 release says its chest CT reporting agent detects 73 thoracic diseases with an average AUC of 95% and that its brain MRI reporting agent identifies 47 neurological conditions from one scan. | 中 | SV006 |
| CV011 | The same RSNA 2025 release warns that the featured products and features may not be available in all countries and that not all AI applications presented are CE-marked or FDA-cleared. | 中 | SV006 |
| CV012 | United Imaging Healthcare's 2025 annual report warns that overseas approvals can involve strong barriers and long registration cycles and that competition from GE Healthcare, Siemens Healthineers, and Philips can pressure market share and pricing. | 中 | SV007 |
| CV013 | Accessible public sources confirm that UII generates revenue from medical AI solutions but do not disclose standalone revenue, EBITDA, or retention, so the $1.4 billion mark cannot be triangulated to an operating multiple from public evidence alone. | 中 | SV001, SV003 |
| CV014 | Yicai reports that United Imaging Healthcare's 2024 revenue was RMB 10.3 billion and attributable net profit was RMB 1.262 billion, down 9.73% and 36.08% year over year. | 中 | SV008 |
| 编号 | 出版方 | 标题 | 引文 |
|---|---|---|---|
| SO001 | United Imaging Healthcare | United Imaging Healthcare Releases 2024 Annual and Q1 2025 Results, Highlights Strong Global Expansion and AI Innovation | In 2024, United Imaging Healthcare remained committed to innovation, with R&D investment reaching 2.26 billion CNY, up 17.84% year-over-year. |
| SO002 | Yicai Global | It plans to increase its capital in United Imaging Intelligence and increase the layout of medical AI | As of December 31, 2023, United Imaging Intelligence's total unaudited assets were RMB313 million, and owners' equity was RMB407 million. In the first three quarters of 2024, the operating income will be 166 million yuan and the net profit will be -82.9218 million yuan, and the operating income will be 254 million yuan and the net profit will be -136 million yuan in 2023. |
| SO003 | IntuitionLabs | United Imaging Intelligence (UII) - Company Profile | This profile was AI-generated from publicly available sources and may contain errors. |
| SO004 | United Imaging | United Imaging Announces Research Collaboration with Massachusetts General Hospital Using Artificial Intelligence to Fight COVID-19 | "The Department of Radiology at MGH proposed leveraging that experience to develop meaningful AI algorithms to help frontline medical professionals detect, predict, and fight COVID-19 in the United States. To that end, we have established a joint research collaboration between United Imaging teams in Shanghai and Boston, and Department of Radiology at MGH." |
| SO005 | United Imaging Intelligence via PR Newswire | United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents | Within uAI Insight, the uAI Agent for Chest CT Reporting demonstrated the ability of detecting 73 thoracic diseases from a single scan with an average AUC of 95%. The uAI Agent for Brain MRI Reporting identified 47 neurological conditions from one scan. |
| SO006 | United Imaging via Hospitals Magazine | United Imaging Showcases Group Synergy and Fosters Global Collaboration at WHX 2026 | At WHX 2026, UII highlighted the uAI Clinical Portal (uCP), featuring over 60 AI applications across imaging modalities and disease areas. |
| SO007 | CMB International Global Markets | United Imaging (688271 CH): Embrace AI: Deep collaboration with United Imaging Intelligence | AI spans the entire clinical workflow, from imaging to therapy and covering diverse modalities including XR , CT, MR, and MI , etc . UII’s main businesses include three segments : 1) Clinical Empowerment (~60 - 70% of business by revenue ): Leveraging AI to assist clinicians in diagnosis, primarily deployed in radiology departments. As of the end of 2024, UII has laun ched over 100 medical AI products and obtained 12 NMPA Class III certificates , 21 NMPA Class II certificates, 13 CE certifications , and 15 FDA certifications . 2) Research Empowerment (~20%): Supporting physicians in research. 3) Equipment |
| SO008 | Multiples | United Imaging Intelligence Valuation, Funding & Investors | United Imaging Intelligence has raised a total of $139M across 1 funding round. |
| SM001 | United Imaging Intelligence | AI SOLUTIONS for HEALTHCARE | More than 40 AI technologies empower all-modalities medical equipment and radiotherapy equipment, spanning the entire diagnostic and treatment process, making imaging and treatment faster, better, safer, and more cost-effective. |
| SM002 | Shanghai United Imaging Healthcare Co., Ltd. | Summary of Shanghai United Imaging Healthcare Co., Ltd. 2025 Annual Report | Against the backdrop of the large-scale medical equipment renewal policy entering a normalized and specialized implementation phase in 2025, demand for equipment related to high-end medical imaging, radiotherapy, and primary-level diagnostic and treatment capacity building continued to be released, and the overall industry scale significantly recovered compared to the same period last year. |
| SM003 | Sina Finance | UNITED IMAGING (688271): Deep Collaboration with United Imaging Intelligence | |
| SM004 | IntuitionLabs.ai | United Imaging Intelligence (UII) - Company Profile | With a significant international footprint, the company has deployed over 100 AI applications across more than 3,000 hospitals globally, focusing on areas such as radiology, surgery, and hospital management. |
| SM005 | United Imaging | United Imaging Announces Research Collaboration with Massachusetts General Hospital Using Artificial Intelligence to Fight COVID-19 | The team will leverage learnings from what it believes to be the largest database of CT images worldwide to develop AI models to be applied to X-ray images. The X- ray models will be refined with U.S. patients, with the target of helping detect and quantify COVID-19, estimating its severity, and exploring other potential use cases. |
| SM006 | United Imaging | United Imaging Healthcare Makes U.S. Market Debut | To support the company's investment in AI, UIH formed United Imaging Intelligence, based in Shanghai, which is focused on embedding AI in UIH's core software across all modalities, and bringing AI further up the imaging chain. |
| SM007 | United Imaging Intelligence via PR Newswire | United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents | These agents spanned diagnostic imaging, surgical care, patient services, hospital operations, and clinical research, illustrating how AI can elevate care at every stage of the patient journey. |
| SM008 | United Imaging via Hospitals Magazine | United Imaging Showcases Group Synergy and Fosters Global Collaboration at WHX 2026 | United Imaging Intelligence (UII), the company’s AI subsidiary, demonstrated how its comprehensive AI portfolio is advancing smart healthcare globally. At WHX 2026, UII highlighted the uAI Clinical Portal (uCP), featuring over 60 AI applications across imaging modalities and disease areas. UII also showcased the uAI Research Portal (uRP), a zero-code platform that streamlines AI development workflow and accelerates research discovery. |
| SP001 | Dealroom | United Imaging Intelligence / 联影智能 — Unicorn company profile | |
| SP002 | Health AI Register | United Imaging Intelligence - Health AI Register | |
| SP003 | IntuitionLabs.ai | United Imaging Intelligence (UII) - Company Profile | |
| SP004 | United Imaging | United Imaging Intelligence at RSNA 2024: Empowering a More Intelligent and Connected World with Medical AI | |
| SP005 | United Imaging | United Imaging Announces Research Collaboration with Massachusetts General Hospital Using Artificial Intelligence to Fight COVID-19 | |
| SP006 | PR Newswire | United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents | |
| SP007 | Sina Finance | UNITED IMAGING (688271): Deep collaboration with United Imaging Intelligence builds an equipment plus AI barrier | |
| SP008 | Yicai Global | United Imaging Healthcare's shareholders completed the inquiry for transfer pricing, and related capital increase to United Imaging Intelligence to promote the layout of medical AI | |
| SI001 | Reuters | United Imaging Intelligence not undertaking an "extreme" AI rollout, says co-CEO | |
| SI002 | United Imaging | UIH Invests $45 Million to Found AI Subsidiary | UIH has invested $45 million to found an artificial intelligence subsidiary. |
| SI003 | Yicai Global | United Imaging Healthcare's shareholders completed the inquiry for transfer pricing, and related capital increase to United Imaging Intelligence to promote the layout of medical AI | On March 18, United Imaging Medical (688271) announced that it intends to increase the capital of its affiliated enterprise Shanghai United Imaging Intelligent Medical Technology Co., Ltd. (hereinafter referred to as "United Imaging Intelligence") with its own funds of 70 million yuan, subscribe for its new registered capital of 3.282906 million yuan, and obtain 0.70% of the equity after the capital increase. |
| SI004 | Yahoo Finance | United Imaging Intelligence not undertaking an "extreme" AI rollout, says co-CEO | |
| SI005 | IntuitionLabs | United Imaging Intelligence (UII) - Company Profile | With a significant international footprint, the company has deployed over 100 AI applications across more than 3,000 hospitals globally, focusing on areas such as radiology, surgery, and hospital management. |
| SI006 | United Imaging | United Imaging Announces Research Collaboration with Massachusetts General Hospital Using Artificial Intelligence to Fight COVID-19 | Teams will leverage experience with thousands of patients to help frontline medical professionals detect, predict, and fight the pandemic. |
| SI007 | Baidu Baike | United Imaging Healthcare Technology Group Co., Ltd. | Shanghai United Imaging Intelligence Medical Technology Co., Ltd. (United Imaging Intelligence) is the artificial intelligence company under United Imaging Group and represents a key strategic deployment for the Group in the field of AI. |
| SI008 | Sina Finance | UNITED IMAGING (688271): DEEP COLLABORATION WITH UNITED IMAGING INTELLIGENCE | |
| SE001 | Shanghai United Imaging Healthcare Co., Ltd. | Summary of Shanghai United Imaging Healthcare Co., Ltd. 2025 Annual Report | The company has built general software and hardware R&D platforms, providing a foundation for technology reference and exchange, as well as product integration and iteration through a cross-product-line platform-based R&D model. |
| SE002 | Physician AI Tools | Shanghai United Imaging Intelligence: Products, FDA Status & Benefits | The company has developed over 10 AI platforms and more than 100 AI applications, with over 50 AI-assisted applications seamlessly integrated to optimize and streamline clinical workflows. |
| SE003 | IntuitionLabs.ai | United Imaging Intelligence (UII) - Company Profile | With a significant international footprint, the company has deployed over 100 AI applications across more than 3,000 hospitals globally, focusing on areas such as radiology, surgery, and hospital management. |
| SE004 | United Imaging | United Imaging Announces Research Collaboration with Massachusetts General Hospital Using Artificial Intelligence to Fight COVID-19 | "United Imaging has developed AI software based on our experience with thousands of patients outside the U.S."explains Dr. Terrence Chen, CEO of United Imaging Intelligence America. |
| SE005 | United Imaging Intelligence via PR Newswire | United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents | Within uAI Insight, the uAI Agent for Chest CT Reporting demonstrated the ability of detecting 73 thoracic diseases from a single scan with an average AUC of 95%. |
| SE006 | RadAISlice | Shanghai United Imaging Intelligence | Radiology AI Companies | uAI Portal is a medical imaging software system developed by Shanghai United Imaging Intelligence Co., Ltd. It provides tools to view, manipulate, and evaluate CT angiography studies focused on vascular structures within various anatomical regions including lower extremities, head and neck, coronary arteries, pulmonary arteries, and aorta. |
| SE007 | United Imaging via Hospitals Magazine | United Imaging Showcases Group Synergy and Fosters Global Collaboration at WHX 2026 | At WHX 2026, UII highlighted the uAI Clinical Portal (uCP), featuring over 60 AI applications across imaging modalities and disease areas. UII also showcased the uAI Research Portal (uRP), a zero-code platform that streamlines AI development workflow and accelerates research discovery. |
| SE008 | Wikipedia | United Imaging | In 2022, United Imaging announced the installation of its 20,000th global system in NY, and in 2024 it announced the shipment of its 30,000th system globally from its Houston manufacturing facility for installation in the U.S. |
| SU001 | United Imaging Healthcare | FAQ | United Imaging Intelligence (Established in December 2017) focuses on the development, production, and sales of AI-driven decision support products. Based in Shanghai with additional R&D centers in Beijing, Wuhan, Chengdu, and the U.S., United Imaging Intelligence plays a crucial role in advancing the Group's artificial intelligence initiatives. |
| SU002 | IntuitionLabs.ai | United Imaging Intelligence (UII) - Company Profile | |
| SU003 | United Imaging | United Imaging Announces Research Collaboration with Massachusetts General Hospital Using Artificial Intelligence to Fight COVID-19 | "The Department of Radiology at MGH proposed leveraging that experience to develop meaningful AI algorithms to help frontline medical professionals detect, predict, and fight COVID-19 in the United States. To that end, we have established a joint research collaboration between United Imaging teams in Shanghai and Boston, and Department of Radiology at MGH." |
| SU005 | United Imaging (syndicated by Hospitals Magazine) | United Imaging Showcases Group Synergy and Fosters Global Collaboration at WHX 2026 | Zhongshan Hospital, one of China’s top-class A tertiary general hospitals, is co-developing and deploying multi-scenario medical AI agents with United Imaging, spanning radiology, interventional radiology, surgery, customer service, EMR, and quality control management—enabling intelligent clinical practice across departments. |
| SU006 | Sina Finance | UNITED IMAGING(688271)：DEEP COLLABORATION WITH UNITED IMAGING INTELLIGENCE | |
| SU007 | Yicai Global | United Imaging Healthcare's shareholders completed the inquiry for transfer pricing, and related capital increase to United Imaging Intelligence to promote the layout of medical AI | After the completion of the transaction, United Imaging Healthcare's cumulative shareholding in United Imaging Intelligence will reach 0.9849%. |
| SU008 | Reuters | United Imaging Intelligence not undertaking an "extreme" AI rollout, says co-CEO | |
| SU009 | United Imaging | United Imaging's Artificial Intelligence Subsidiary Wins in Facebook AI Research & NYU School of Medicine Global Competition | The company's United Imaging Intelligence America subsidiary led out of Boston won top prize in the multi-coil 4x acceleration category, a clinically relevant challenge designed to accelerate MRI scans using artificial intelligence (AI). |
| SU010 | Multiples.vc | United Imaging - Multiples.vc - Public Comps and Valuation Multiples | On 20th June 2025 United Imaging invested in United Imaging Intelligence, participating in a $139M Series A round at $1.4B valuation |
| SR001 | Inside AI | China’s United Imaging Intelligence Resists Extreme AI Rollout in Healthcare | “In healthcare, in medicine, the first mover advantage is not as drastic as other fields,” Zhou said, highlighting the sector’s unique risk profile where errors can directly harm patients. |
| SR002 | Reuters | United Imaging Intelligence not undertaking an “extreme” AI rollout, says co-CEO | “Some companies said … if you don’t use this much token, you must not be transforming into the new age. We are not that extreme,” Zhou said, adding software engineers and architects had warned him about potential side effects because the technology remained insufficiently mature. |
| SR003 | Shanghai United Imaging Healthcare Co., Ltd. | Summary of Shanghai United Imaging Healthcare Co., Ltd. 2025 Annual Report | The company primarily adopts a sales model combining distribution and direct sales. During the reporting period, distribution revenue from the company's main business was 8.41 billion yuan, accounting for 63.91% of the main business revenue. |
| SR004 | United Imaging | United Imaging Announces Research Collaboration with Massachusetts General Hospital Using AI to Continue Fighting COVID-19 | "United Imaging has developed AI software based on our experience with thousands of patients outside the U.S."explains Dr. Terrence Chen, CEO of United Imaging Intelligence America. |
| SR005 | PR Newswire | United Imaging Intelligence at RSNA 2025 | Products and features referenced may not be available in all countries, and future availability cannot be guaranteed. Not all AI applications presented are CE-marked or FDA-cleared. |
| SR006 | Hospitals Magazine | United Imaging Showcases Group Synergy and Fosters Global Collaboration at WHX 2026 | uMetaGenesis transforms equipment operational data into actionable, real-time insights—enabling proactive maintenance strategies and minimizing unplanned scanner downtime. |
| SR007 | multiples.vc | United Imaging Intelligence Valuation, Funding & Investors | United Imaging Intelligence is currently valued at $1.4B, based on its Series A in June 2025. |
| SR008 | Huatai Securities via Sina Finance | UNITED IMAGING (688271): DEEP COLLABORATION WITH UNITED IMAGING INTELLIGENCE | |
| SV001 | Preqin | United Imaging Intelligence Asset Profile | Preqin | In October 2025, United Imaging Intelligence raised CNY 1 billion in venture funding from new investors Shanghai United Imaging Healthcare Co. , Ltd. , United Imaging Group, and new investor Shanghai Alliance Investment. |
| SV002 | Fineline Info & Tech / FLCube | United Imaging Intelligence Closes RMB 1B Series A Round to Boost AI in Healthcare | United Imaging Intelligence, the AI-focused subsidiary of Shanghai United Imaging Healthcare Co., Ltd., reportedly secured RMB 1 billion (USD 139 million) in a Series A financing round. The funding was co-led by E Fund Management and SIG Property Management, with participation from Shanghai Alliance Investment, Sun Rock Capital, Suzhou Capital Group, Tsing Song Capital, and United Imaging, among others. |
| SV003 | Multiples | United Imaging Intelligence Valuation, Funding & Investors | Multiples | United Imaging Intelligence is currently valued at $1.4B, based on its Series A in June 2025. |
| SV004 | Sina Finance | UNITED IMAGING (688271): DEEP COLLABORATION WITH UNITED IMAGING INTELLIGENCE | ����Full-stack and full-spectrum AI solutions, empowering medical scenarios from multiple dimensions. UII��s full-stack and full-spectrum medical imaging AI spans the entire clinical workflow, from imaging to therapy and covering diverse modalities including XR, CT, MR, and MI, etc. UII��s main businesses include three segments: 1) Clinical Empowerment (~60-70% of business by revenue): Leveraging AI to assist clinicians in diagnosis, primarily deployed in radiology departments. As of the end of 2024, UII has launched over 100 medical AI products and obtained 12 NMPA Class III certificates, 21 NMPA Class II certificates, 13 CE certifications, and 15 FDA certifications. 2) Research Empowerment (~20%): Supporting physicians in research. 3) Equipment Empowerment (~10%): Collaborating with United Imaging to enable intelligent upgrades and performance enhancements of medical devices. |
| SV005 | United Imaging | United Imaging Announces Research Collaboration with Massachusetts General Hospital Using Artificial Intelligence to Fight COVID-19 | "United Imaging has developed AI software based on our experience with thousands of patients outside the U.S."explains Dr. Terrence Chen, CEO of United Imaging Intelligence America. "The Department of Radiology at MGH proposed leveraging that experience to develop meaningful AI algorithms to help frontline medical professionals detect, predict, and fight COVID-19 in the United States. |
| SV006 | United Imaging Intelligence | United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents | Within uAI Insight, the uAI Agent for Chest CT Reporting demonstrated the ability of detecting 73 thoracic diseases from a single scan with an average AUC of 95%. The uAI Agent for Brain MRI Reporting identified 47 neurological conditions from one scan.... Not all AI applications presented are CE-marked or FDA-cleared. |
| SV007 | Shanghai United Imaging Healthcare Co., Ltd. | 上海联影医疗科技股份有限公司2025年年度报告 | Some countries have historically had strong approval barriers for the operation and sales of high-end medical devices, with long time cycles for product registration and significant difficulties in market access.... Facing international market competition, if the company cannot maintain and continuously strengthen its competitive advantages and core competitiveness, the market share and price of its products may decline due to intensified market competition. |
| SV008 | Yicai Global | United Imaging Healthcare's shareholders completed the inquiry for transfer pricing, and related capital increase to United Imaging Intelligence to promote the layout of medical AI | After the completion of the transaction, United Imaging Healthcare's cumulative shareholding in United Imaging Intelligence will reach 0.9849%. The capital increase also includes the controlling shareholder United Imaging Group, the shareholder Shanghai Lianhe and other related parties, who participated in this round of financing with a shareholding ratio of 2% and 1.7901% respectively. |